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Summary 
The T regulatory cells (Tregs) play an important role in immune homeostasis, by maintaining 
tolerance to self-antigens and allergens as well as by limiting inflammatory tissue damage 
during chronic infections. Humans or mice lacking the Treg-associated transcription factor 
FOXP3 develop severe features of autoimmunity and allergy. Ectopic FOXP3 expression 
endows non-regulatory T cells with many of the hallmarks of regulatory T cells and 
transgenic reporter mice carrying a FOXP3-GFP indicated that FOXP3 expression correlates 
with suppressive T cells. Therefore FOXP3 is a faithful marker for Tregs. 
Although Tregs can be generated in the thymus, their induction out of non-Tregs was also 
revealed in the periphery. The molecular mechanisms leading to Tregs generation in the 
periphery are still not identified. To gain insight into this key process we analyzed peripheral 
FOXP3 regulation. For this purpose we localized and cloned the human FOXP3 promoter 
into a reporter plasmid and characterized its activity in primary CD4+ T cells. In a second 
step, we looked at factors, which regulate FOXP3 expression during the differentiation 
process from naïve T cells into the effectors cells. 
This thesis reveals that the FOXP3 promoter is located -6221 bp upstream of the translation 
start site and the 5’ UTR is interrupted by a 6000 bp intron. Our results indicate that the 
FOXP3 promoter is cell-specific and is active only in primary CD4+ T cells. 
We demonstrated that FOXP3 mRNA and protein expression is induced following TCR 
engagment in CD4+CD25- T cells or artificially by phorbol 12-myristate 13-acetate (PMA) 
and ionomycin induced FOXP3 promoter activity. The activation-responsive element of the 
FOXP3 promoter is composed of at least three NFAT and AP-1 sites. 
Cyclosporin A (CsA) completely inhibited the mRNA induction of FOXP3 as well as the 
promoter activity. CsA is a well-known immunosuppressive drug, which blocks NFAT 
translocation into the nucleus by inhibition of the calcineurin phosphatase activity. We have 
shown that the immunosuppressants glucocorticoids and rapamycin promote FOXP3 
expression. Therefore immunosuppressive drugs may have different mechanisms to promote 
immune tolerance and a more precise knowledge of the immunosuppressive drugs targets 
will improve their therapeutical usage. 
Although induction of FOXP3 upon TCR triggering is probably an important step, it remains 
unclear, which signals are specifying Tregs induction over the induction of effector Th1 or 
Th2 cells. 
We demonstrated that Th2 commitment prevents the induction of FOXP3+ Treg cells by a 
GATA3-dependent mechanism., in contrast to naïve T cells cannot in vitro differentiated Th2 
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cells express FOXP3 upon stimulation with TGF-β. The Th2 cytokine IL-4 efficiently 
inhibited FOXP3 mRNA and protein expression in differentiating naïve human T cells.  
We investigated the role of GATA3 in this process, since it is known to be essential for Th2 
commitment and is induced by IL-4. Transient overexpression of GATA3 blocked the 
induction of the FOXP3 promoter activity in human T cells and strikingly, mice engineered 
to overexpress GATA3 in T cells (CD2-GATA3 x DO11.10 Tg mice) do not express FOXP3 
following TGF-β exposure along with the specific antigen. We discovered that these GATA3 
effects are mediated by a direct action on the FOXP3 promoter. We described a GATA3 
binding site in the FOXP3 promoter, between the NFAT-inducible region and the 
transcription start site. Site-specific mutation of this GATA3 binding region, which is 
accessible on the chromatin level, reveals that this element negatively regulates the FOXP3 
promoter activity. 
Taken together this thesis revealed that antigen-experience is an important step in Treg 
generation. We identified GATA3 as a negative regulator of FOXP3 expression, which 
suggests that Treg induction relative to Th1 or Th2 differentiation is a matter of negative 
cross-regulation of competing lineage-specific factors. This mechanism is likely to improve 
our understanding of Treg induction and thus the induction of immune tolerance in disease 
such as allergy or autoimmunity. 
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Zusammenfassung 
Regulatorische T-Zellen (Tregs) halten die Immuntoleranz gegenüber Selbstantigen oder 
Allergen aufrecht, in dem sie die entzündliche Gewebezerstörung begrenzen. Die Tregs sind 
durch die Expression von FOXP3 gekennzeichnet, welches im Falle von genetischen 
Defekten zu schweren Autoimmunerkrankungen und allergischer Entzündungen führt. 
Artifizielle FOXP3-Überexprimierung verleiht normalen T Zellen das phänotypische 
Erscheinungsbild von Tregs. Studien über transgene Reporter Mäuse (FOXP3-GFP) zeigen, 
dass die FOXP3 Expression mit aktiven suppressor-T-Zellen korreliert. Dem zufolge ist 
FOXP3 ein wichtiger Indikator für Tregs, welche in der Regel im Thymus generiert werden. 
Interessanterweise konnte kürzlich gezeigt werden, dass Tregs auch in der Peripherie 
induziert werden können und somit auch bei der Toleranz von Allergenen wichtig sein 
könnten.  
Die molekularen Mechanismen der Treg Induktion in der Peripherie sind noch nicht erforscht 
worden. Gegenstand dieser Studie ist daher der Prozess der peripheren Treg Induktion.  Das 
FOXP3-Gen wurde als wichtige molekulare Leitstruktur verfolgt. Dementsprechend wurde 
der humane FOXP3 Promoter lokalisiert und in einen Luciferase-Vektor kloniert, um dessen 
Aktivität in primären humanen T-Zellen zu bestimmen. Ausserdem wurden Faktoren 
lokalisiert, die die FOXP3-Expression während der T-Zell-Differenzierung regulieren.  
Die vorliegenden Ergebnisse zeigen, dass der FOXP3-Promoter -6221 bp aufwärts von der 
Translation Start-Stelle liegt und zu der 5’-UTR durch ein 6000 bp Intron unterbrochen ist. 
Die Studie beschreibt ausserdem die Zell-spezifische Aktivität des FOXP3-Promoters, die 
sich nur in primären CD4+ T-Zellen darstellen lässt.  
Die FOXP3 mRNA- und Proteinexpression wird durch die T-Zell-Rezeptor (TCR) 
Aktivierung oder artifiziell durch phorbol 12-myristate 13-acetate (PMA) und Ionomycin 
induziert. Die aktivierungsabhängigen Elemente des FOXP3-Promoters sind aus mindestens 
drei NFAT und mehrere AP-1 Bindungsstellen aufgebaut. 
Cyclosporin A (CsA) inhibiert sowohl die FOXP3 mRNA- und Proteinexpression, als auch 
die FOXP3-Promotoraktivität. CsA ist ein weitverbreitetes, immunsupressives Medikament, 
dessen Wirkung auf der Blockierung des NFAT beruht. Es §wird deutlich, das 
immunsupressive Medikamente in unterschiedlicher Art und Weise die Immuntoleranz über 
Tregs beeinflussen kann. Das Verständnis des Wirkmechanismus bezüglich des FOXP3 und 
der Treg-Induktion wird den Einsatz dieser Medikamente hinsichtlich der Immuntoleranz 
verändern und die therapeutischen Anwendungen erweitern.  
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Obwohl die Induktion des FOXP3 bzw. der Tregs von dem TCR abhängt, bleibt die 
Spezifität der Treg-Induktion gegenüber den Effektor Th1 oder Th2 Zellen unklar. In der 
vorliegenden Arbeit zeigen wir erstmals, dass die Th2-Differenzierung die Induktion von 
FOXP3+ Tregs über einen GATA-3 abhängigen Mechanismus verhindert. In Gegensatz zu 
naïven T-Zellen können in vitro differenzierte Th2-Zellen kein FOXP3 exprimieren. 
Bei unserer Analyse des zugrundeliegenden Mechanismus konnten wir die wichtige Rolle des 
GATA-3 beweisen, welches für die Th2-Differenzierung unersetzlich ist und durch IL-4 
induziert wird. Die transiente Überexpression von GATA-3 blockiert die Induktion der 
FOXP3-Promoter Aktivität in humanen T-Zellen. In Mäusen, die genetisch so verändert 
wurden, dass sie GATA-3 nur in T-Zellen exprimieren, konnte im Gegensatz zu den Wild-
Typ Mäusen keine FOXP3-Induktion nach TGF-β- und Antigen-Stimulation beobachtet 
werden. Es konnte bewiesen werden, dass GATA-3 an eine Stelle im FOXP3-Promoter 
bindet, die zwischen der NFAT-induzierbaren Region und der Transkriptions-Start-Stelle 
liegt. Die im Chromatin zugängliche GATA-3 Bindestelle inhibiert die FOXP3-Expression, 
wie es durch die Sequenz-spezifische Mutation bewiesen werden konnte. 
Zusammenfassend lässt sich auf Grund der vorliegend Doktorarbeit feststellen, dass Antigen-
Kontakt eine Schlüsselrolle in der Treg-Induktion spielt. Die GATA-3 vermittelte negative 
Regulation des FOXP3-Gens lässt vermuten, dass die Spezifität der Treg-Induktion durch 
negative Regulations-Mechanismen zustande kommt. Dieser Mechanismus ist wichtig für die 
immunologischen Konzepte der Treg- und Toleranzinduktion bei Allergien und 
Autoimmunerkankungen.
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Abbreviations 
    
APC      Antigen-Presenting cells 
AIDS      Aquired immunodeficiency syndrome 
BTEB1     Basic transcription element binding protein 1 
CD      cluster of differentiation  
CsA      Cyclosporin A 
CTL      Cytotoxic T cells 
CTLA-4     Cytotoxic T lymphocyte antigen 4 
DC       Dendritic cell 
DNMT     DNA methyltransferase  
EAE      Experimental autoimmune encephalomyelitis  
FOG      Friend of GATA 
GITR      Glucocorticoid-induced tumor necrosis factor 
       receptor family-related receptor 
GVDH      Graft-versus host disease 
IFN      Interferon 
IL       Interleukin 
GPI      Glycosylphosphatidylinositol 
LPS      Lipopolysaccharide 
MAPK      Mitogen-activated protein kinase 
MHC       Major histocompatibility complex 
MBD2      methyl-CpG binding domain protein-2  
MBP      Myelin basic protein 
MS      Multiple sclerosis 
NFAT      Nuclear factor of activated T cells  
NuRD      nucleosome remodeling and deacetylase 
OVA      Ovalbumin 
PAMP Pathogen-associated molecular patterns   
PD-1       Programmed death-1 
PMA      Phorbol 12-myristate 13-acetate  
ROG      Repressor of GATA 
STAT6     signal transducer and activator of transcription 
TCR       T cell receptor    
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TGF-β      Transforming growth factor-β 
Th       T helper cell    
TLRs       Toll-like receptors    
Tr1      T regulatory 1 
TSLP      Thymic stromal lymphopoetin 
TSS      Translation start site 
TIEG2      TGF-β-inducible early protein gene 2 
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1. Introduction 
1.1. Overview 
The human organism is continuously exposed to microorganisms, which constitute a 
potential danger to the host. The immune system, which fights against pathogens, has the 
difficult task to distinguish between harmless and harmful antigens. Although the protection 
against infections is fundamental for the survival of all animals, an immune reaction to self or 
innocuous antigens may cause severe disease leading to autoimmunity or allergies with in 
some cases fatal consequences. Therefore the immune system has developed an efficient 
barrier to identify pathological microorganisms and to actively maintain tolerance to 
innocuous antigens. The immune system is divided into two parts: innate and adaptive.  
The innate immune system is the first line of defense against pathogenic microorganisms 
(bacteria, viruses, fungi, and parasites). Once activated, the cells produce cytokines that 
regulate and coordinate many activities of the cells from the innate and adaptive immune 
system. Innate immunity is activated by specific structures, which are common to different 
microbes but does not allow an efficient defense against the invading pathogens, which are 
structurally variable and is therefore complemented by the adaptive immune system. The 
adaptive immunity may take days or weeks, after an initial infection, to have an effect.  It is 
composed of humoral and cell-mediated immunity including B cell, CD8 cytotoxic T cells 
(CTL) and the effector or T helper cells (Th). The T helper cells produce cytokines that 
activate macrophages and induce proliferation of B and T cells.  Innate and adaptive systems 
communicate to build an efficient way of fighting pathogens.  
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1.2. The innate immune system tailors the adaptive immune 
response 
 
The specific immune response is driven by effector cells composed of the Th1, Th2 and Th17 
cells. The Th1/Th2/Th17 response is further controlled by T regulatory cells (Tregs), which 
are potent suppressors of the immune system. The immune response is a dynamic process, 
which has to be adapted for the specific invading pathogens, in order to efficiently clear the 
infection. In addition the immune response may tend toward tolerance, instead of activation 
and elimination of the microbes. Therefore, an accurate communication has developed 
between the innate immune system, which encounters first the pathogen and the adaptive 
immune system, which fights specifically and efficiently against antigens.  
The “innate” receptors, Toll-like receptors (TLRs), mannose receptor recognize conserved 
pathogenic particles called pathogen-associated molecular patterns (PAMPs) expressed by 
microbes such as lipopolysaccharide (LPS) and triggers a type 1 response (Th1 cells) 
characterized by a high IFN-γ secretion. For example, viruses, which infect the cells, will be 
recognized by the intracellular TLRs, which bind to the ssDNA or dsRNA typical from 
viruses. HSV-2 triggers a potent type I interferon response by activating the TLR9 from the 
plasmacytoid dendritic cells (DCs). This interferon secretion leads to the anti-viral state, 
characterized by inhibition of viral replication, increase effectiveness of CTL-mediated 
killing of infected cells and stimulation of Th1 cell development 1-4. Intracellular bacteria are 
engulfed by phagocytes, in which they can survive, but during this intracellular persistence, 
the pathogens are degraded and presented to the CD4+ T cells, which in turn secrete IFN-γ 
increasing the phagocytic activity of the phagocytes and lead to the elimination of the 
bacteria. Furthermore macrophages secrete IL-12, which induces differentiation of naïve T 
cell into the IFN-γ-secreting Th1 cells 5. Therefore a Th1 response is generated in response to 
infections by viruses or intracellular bacteria. The critical role of T cells is demonstrated by 
patients suffering from acquired immunodeficiency syndrome (AIDS), who are extremely 
susceptible to infections by intracellular bacteria 6,7 and further illustrates that innate and 
adaptive immune systems collaborate in order to fight efficiently against pathogens 8,9. 
Although this interconnection between innate immunity is better understood in the generation 
of a type 1 immune response, innate receptors have also been reported to efficiently generate 
a type 2 immune response, characterized by Th2 cells, which secrete the cytokine IL-4. Th2 
cells are fighting helminth infections by modulating the antibody response. Allergy is an 
 14 
immune disorder characterized by an exuberant Th2 cell activity, resulting in a switch from 
IgM to IgE production in B cells 10. Allergens are proteins, often enzymes, and are normally 
harmless, but provoke a reaction in allergic patients already at low concentrations (ng - µg 
range) 10. IL-4 is the most potent factor inducing differentiation into Th2 cells in vitro. The 
origin of the Th2-driving forces in vivo are not clear, since several cells secrete IL-4 in basal 
conditions: Th2, basophiles, mast cells and eosinophils. After differentiation, Th2 cells 
secrete IL-4. This effect would propagate as CD4+ effector cells are differentiating at the 
antigen presentation site, leading to a threshold in IL-4, which drives the expression of the 
Th2 profile. The pathogens, which are first recognized by the cells of the innate immune 
system, influence the maturation stage of APCs and thus the strength of the TCR signal and 
costimulation that receive the T cells. In addition pathogens affect the cytokines produced by 
the innate system and therefore the immune polarization and differentiation into the different 
effector lineages.  
The naïve T cells require 3 signals in order to differentiate into effector cells, TCR 
stimulation, costimulation and cytokines. The first signal is the TCR stimulation by the 
peptide presented on the major histocompatibility complex class II (MHCII) of an antigen-
presenting cell (APC), only T cells with a TCR specific for the antigen-MHC II complex will 
be activated, providing the antigen-specificity of the immune response. Depending on its 
strength, TCR stimulation influences the differentiation of cells. Strong stimulation leads to 
Th1 commitment, while weak antigen stimulation favors differentiation into Th2 11,12. The 
second signal is given by costimulation, which is an important stimulus, since a lack of this 
signal leads to anergy (unresponsive state). The costimulatory molecules can be divided into 
activators or inhibitors of the immune response: CD28, ICOS stimulation potently induces 
the T cell activation and cytokine secretion whereas cytotoxic T lymphocyte antigen 4 
(CTLA-4), PD1 act as inhibitory molecules 13-20. The third signal is given by the cytokines 
secreted by cells of the innate immune system or in an autocrine fashion.  
The type I polarizing factors are IL-12 5,21, IL-23 22 and IL-27 23,24. IL-12, IL-23 and Il-27 all 
belong to the same cytokine family 25 and are mostly produced by activated monocytes, 
macrophages, neutrophils and dendritic cells. These cytokines induce STAT1 26,27, STAT4 28 
and T-bet 29, which are triggering the production of IFN-γ 30, the typical Th1 cytokine. 
The type 2 polarizing factors are mainly IL-4 and notch ligands 31-36 that lead to the induction 
of the IL-4-secreting Th2 cells. In addition, tolerance might be induced by modulation of the 
DCs function. Induction of dendritic cells maturation by pathogens is a key process in naïve 
T cell differentiation into Th1 and Th2 cells. In the steady state, dendritic cells are immature 
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and provide a tolerogenic environment. Key cytokines for converting dendritic cell into more 
professional tolerogenic cells are IL-10 and TGF-β 37. 
 
 
 
Figure 1: Polarization of the adaptive response by the innate immune system. The pathogens can 
be categorized into type 1, type 2 or tolerizing pathogens depending on the response induced. The 
pathogens affect maturation of the DCs or other APCs and cytokine secretion by the cells of the 
innate immune system, inducing the differentiation of antigen-specific naïve T cells into different 
subsets, adapted from 38. 
 
Several pathogens take advantage of this fundamental strategy of the immune system and 
have developed strategies to escape the immune system by inducing regulatory DCs. 
Regulatory or tolerogenic DCs are characterized by reduced expression of costimulatory 
molecules in particular CD40, CD80, CD86, reduced IL-12 and increased IL-10 production 
39. 
IL-10 has been shown in vitro to induce differentiation of immature DC into tolerogenic DC, 
which promote the generation of a subset of IL-10-secreting regulatory T cells (Tr1) 40. 
Plasmodium falciparum 41,42, Mycobacteria 43,44, hepatitis C 45, herpes simplex virus 46, 
cytomegalovirus 47, S. mansoni 48, bordetella pertussis 49 induce tolerizing dendritic cells, 
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giving rise to tolerance  and chronic infection. Therefore differentiation of effector cells from 
naïve cells is a complex process occurring in a very dynamic environment, under the 
scrutinity of the innate immune system, which tailors the adaptive response to generate a 
strongly adapted and efficient response to the invading pathogens (Figure 1). 
The Th1 and Th2 cells were discovered first by Mosmann. He suggested that the immune 
system response to pathogens involves the production of two clusters of cytokines with 
antagonistic effect for the other subset 50-52. Each cell subset secretes a pattern of cytokines 
determining the functional diversity of CD4+ memory T cells and type of induced immune 
response.  
The ability of mounting a Th1 or Th2 response is strongly under control of genetic factors as 
illustrated by the Th1-prone C57BL/6 and the Th2-prone Balb/C mice strains. The Balb/C 
mice are highly susceptible to induced asthma and inefficient in mounting a Th1 immune 
response to the intracellular parasite Leishmania major 53. On the other hand, C57BL/6 are 
not susceptible to asthma induction and clear efficiently infections by L. major 54,55. 
In addition, environmental factors play an important role. In the last twenty years, the 
incidence of atopy in developed countries increased dramatically 56, probably as a 
consequence of the decrease of infections with type I polarizing pathogens during childhood 
due to improved hygiene in the industrialized world 56. However, the role of Th1 responses 
downregulating Th2 responses is still controversial since atopic children infected with 
influenza virus exacerbate the symptoms of asthma. Thus, respiratory viral infection and the 
acute Th1 response can positively regulate Th2-dependent allergic pulmonary disease in vivo, 
at least in part 57, indicating that other cells might be involved in the regulation of the 
Th1/Th2 balance. Indeed T regulatory cells with potent in vitro and in vivo suppressive 
capacity regulate the Th1 and Th2 cells 58-61 and control the T cell response. The Th17 cells 
belong to another cell lineage, which produces IL-17. The discovery of Th17 and inducible 
Treg, which can differentiate from the same precusor cell, the naïve T cell, further completes 
the Th1/Th2 paradigm. At least four different T cell lineages, characterized by their cytokine 
profile and functions, can differentiate from the naïve T cells. Treatment of naïve T cells with 
TGF-β induces cells with regulatory properties (Tregs), which are able to suppress activation, 
proliferation and cytokine production of CD4 cells. Tregs are characterized by their 
suppressive function and constitutive expression of CD25 and FOXP3 62-64. Interestingly 
when IL-6 is added to TGF-β at the time of priming, the induction of Treg is inhibited 
leading to the generation of Th17 cells 65-67, which are characterized by a potent pro-
inflammatory capacity. These cells have been described in several autoimmune conditions 
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65,68,69. However, the molecular mechanisms involved in Treg and Th17 cells generation are 
still not known (Figure 2). 
 
 
Figure 2: Different subsets of T effector cells can be generated out of naïve T cells. The cytokines 
present at the time of priming of the naïve cells lead to Th1, Th2, iTregs and Th17. Although they 
originate from the same precursors the cells have very different functions. 
 
1.2. Mechanisms of Th2 cells differentiation 
Type 2 responses are characteristic of the beneficial immune response to helminth parasitic 
infection, but also of the inappropriate immune response leading to allergy and asthma 70, 
graft-versus host disease (GVDH), progressive systemic sclerosis, systemic lupus 
erythematosus 71. Il-4 is a potent Th2-driving cytokine in vitro, but the mechanisms of Th2 
cells differentiation in vivo are in contrast to Th1 cells far from being fully understood. The 
cellular sources of IL-4 during an allergic reaction or helminth infections are not well-defined 
and may depend on the localization and the antigen type. Mast cells, basophils, NKT cells 
and previously differentiated Th2 cells display high basal levels of IL-4 mRNA and can 
rapidly release IL-4 upon stimulation. Indeed, it has been shown that IL-4 production during 
Nippostrongylus Brasiliensis infection develops independently of the adaptive immune 
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system, but comes rather from cells of the innate immune system. IL-4 production by Th2 
cells is then more important for the effector phase to maintain a type 2 polarized immune 
response 72-74. 
Th2 cells are characterized by the production of the closely related IL-4, IL-5 and IL-13, 
whereas these genes are silenced in Th1 cells 75. They are located in the same cluster on 
chromosome 5 in humans 76 and 11 in mice 76. The initiation phase of the differentation 
process occurs as the TCR is triggered by antigen and consists of a complex array of 
epigenetic changes and transcription factor expression and induction, which leads to the 
characteristic cytokine profile expression.  
Naïve T cells express the IL-4 receptor, a heterodimer composed of the specific IL-4Rα 
subunit and the common γ-subunit 77. Upon binding to its receptor, IL-4 can initiate the 
phosphorylation and activation of Stat6. Activated Stat6 will form a dimer, which enables it 
to enter the nucleus where it will, together with NFAT, AP-1 NF-κB and other TCR-induced 
signals activate the transcription of GATA3 and IL-4 78,79. Autocrine IL-4 production per se 
reinforces Th2 differentiation.  
Thus, Stat6 is a central mediator of the IL-4 signal involved in Th2 development 80,81. The 
importance of IL-4 and Stat6 in Th2 differentiation has been demonstrated by the generation of 
IL-4 or Stat6 target-specific deficient mice. CD4 T cells from IL-4-deficient mice have a defect 
to mount a Th2 response or produce IL-5 and IL-13 after in vivo challenge 82,83. Similarly, in 
Stat6-deficient mice, Th2 differentiation was blocked, and IgE titers in response to N. 
brasiliensis are dramatically decreased 81,84. 
Stat6 is involved in direct regulation of GATA3 expression, a transcription factor 85, which also 
increases Th2 cell differentiation. 
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Figure 3: Induction of Th2 cell differentiation. IL-4, TCR signaling and costimulation trigger Th2 
cell differentation by inducing STAT-6, NFAT, NFκB and GATA3. These transcription factors 
collaborate to mediate chromatin remodeling of the IL-4, IL-5, IL-13 locus and activate gene 
transcription. 
 
1.2.1. GATA3 is a master regulator of Th2 cells differentiation 
Naïve T cells express a basal level of GATA3, which is upregulated in the course of Th2 
differentiation and extinguished during Th1 differentiation 86. GATA3 expression in primary 
T cell is dependent on TCR activation and is blocked by the NF-κB inhibitor SN50. In 
addition, mice that lack the p50 subunit of NF-κB are unable to mount airway eosinophilic 
inflammation due to the inability of the p50-/- mice to produce IL-4, IL-5 and IL-13: 
cytokines that play a key role in asthma pathogenesis. CD4+ T cells from p50-/- mice failed 
to induce GATA3 expression under Th2-differentiating conditions, but showed unimpaired 
T-bet expression and IFN-γ production under Th1-differentiating conditions. Inhibition of 
NF-κB activity prevents GATA3 expression and Th2 cytokine production in developing, but 
not in committed Th2 cells 87,88.  
Regulation of cytokine gene expression is strongly mediated by chromatin remodeling 
characterized by histone acetylation and DNA methylation. GATA3 has been shown to 
induce chromatin structure remodeling of the Th2 locus IL-4, IL-5, IL-13 and IL-10 allowing 
access to the transcriptional machinery 75,89,90. Overexpression of GATA3 in Th cells induces 
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the appearance of the Th2-specific DNase I-hypersensitive sites II, III, and V of the il4 gene 
as well as the hyperacetylation and demethylation of the il4 locus 75,91,92. In addition, 
conditional inactivation of the gata3 gene leads to decreased histone acetylation and 
increased DNA-methylation of the IL-4 locus 91. It has been shown that GATA3 inhibits and 
competes with the binding of the methyl-CpG binding domain protein-2 (MBD2) to the 
second intron of the il4 gene and to CNS-1 and thus the recruitment of a silencing complex 93. 
MBD2 is capable of recruiting the multiprotein nucleosome remodeling and deacetylase 
(NuRD) repressive complex 94. In the MBD2 -/- mice, GATA3 is not necessary for heritable 
induction of IL-4 and the progeny express substantial levels of IL-4. 
CD4+ single-positive thymocytes express IL-4, but attenuate GATA3 expression, and recruit 
DNA methyltransferases (Dnmts) to the Il4-Il13 locus and downregulate IL-4 expression as 
they mature into T cells. Type 2 polarization blocks Dnmt1 recruitment, enhances histone 
H3 Lys4 methylation (indicative of accessible chromatin) and initiates DNA demethylation 
of the locus. Dnmt1-/- CD4 and CD8 T cells derepress IL-4 expression considerably, 
demethylate DNA and increase H3 Lys4 methylation without affecting GATA3 expression, 
demonstrating that Dnmt1 and DNA methylation are essential for proper Il4 regulation. 
These data indicate that Dnmts, DNA as well as histone methylation, and transcription 
factors work together in determining appropriate Il4 expression patterns 95. 
In addition to its role in remodeling chromatin, GATA3 acts by directly transactivating the 
promoter of IL-5, IL-13 96,97 and the enhancer of IL-4 79,98. Investigations using transgenic 
mice containing the murine Th2 cytokine cluster carrying an IL-4 promoter-luciferase 
reporter showed that IL-4 promoter activity in effector CD4 T cells from these transgenic 
mice was strong, and importantly Th2 specific. Expression of the IL4 promoter reporter was 
transactivated in vivo by GATA3 99. 
In fact reduction of GATA3 expression in cloned Th2 cells by antisense RNA led to a 
reduction of IL-4, IL-5, IL-6, IL-10 and IL-13 Th2 cytokine mRNA and protein secretion 100. 
Interestingly, GATA3 does not only promote Th2 cells commitment by increasing 
transcription of Th2 cytokines, but also by repressing Th1 commitment. GATA3 interferes 
with IL-12 signaling by downregulating STAT4, which is necessary for IFN-γ production 
101,102.  
The different studies demonstrate that GATA3 is the master transcription factor in Th2 cell 
differentiation. In addition to GATA3, cMaf and JunB, two bZIP transcription factors are 
expressed specifically in Th2 cells and bind to the IL-4 proximal promoter 103-106. 
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Overexpression of c-Maf in non-T cells induced IL-4 mRNA expression. Furthermore, c-
Maf-/- mice secrete less IL-4 107. JunB, a member of the AP-1 transcription factor family, 
acts synergically with c-Maf to induce IL-4 expression. 
Importantly GATA3 autoactivates its own transcription in a stat-6-independent mechanism, 
giving rise to a positive feedback that stabilizes and reinforces Th2 commitment 108. 
GATA3 expression is not only essential for Th2 cell differentiation but also for maintenance 
of established chromatin remodeling at the Th2 cytokine gene loci, including Th2-specific long 
range histone hyperacetylation of the IL-13/IL-4 gene loci. By using a Cre/LoxP-based site-
specific recombination system in cultured CD4 T cells, Yamashita et al. investigated the 
effect of loss of GATA3 expression by in vitro differentiated Th2 cells. After ablation of 
GATA3, the production of all Th2 cytokines was reduced, the DNA methylation at the IL-4 
gene locus was increased, and histone hyperacetylation at the IL-5 gene was decreased. Thus, 
GATA3 plays important roles in the maintenance of the Th2 phenotype and continuous 
chromatin remodeling of the specific Th2 cytokine gene locus through cell division 90. 
 
1.2.2. Flexibility of commitment 
Once a cell has been committed into a certain T cell subset, the phenotype is imprinted and 
will be inherited by the sister cells. Therefore, CD4+ T cell priming under Th1 or Th2 
polarization conditions gives rise to polarized cytokine gene expression. In these conditions, 
human naive T cells acquired stable histone hyperacetylation at either the Ifnγ or Il4 
promoter. But some flexibility is possible, hypoacetylation of the nonexpressed cytokine gene 
does not lead to irreversible silencing, restimulation of Th1 or Th2 cell clones into Th2 or 
Th1 conditions resulted in cells producing both IL-4 and IFN-γ. Thus, the chromatin acquires 
also an open conformation in the previously closed and repressed chromatin. But some cells, 
from central memory expressing CRTh2, a prostaglandin D2 receptor expressed by some Th2 
cells, failed to upregulate T-bet and to express IFN-γ when stimulated under Th1 conditions 
109,110. Thus, most human CD4+ T cells retain both memory and flexibility of cytokine gene 
expression. 
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1.3. Immune tolerance 
 
Immunologic tolerance is defined as unresponsiveness to an antigen that is induced by 
previous exposure to that antigen. When specific lymphocytes encounter antigens, the 
lymphocytes may be activated, leading to immune responses, or the cells may be inactivated 
or eliminated, leading to tolerance. In order to avoid an immune response against self-antigen 
and harmless antigen, several mechanisms have evolved, including deletion of self-reactive 
cells in the thymus in a process called central tolerance, as well as deletion, anergy and active 
suppression by Tregs in the periphery. 
 
1.3.1. Central tolerance 
The first mechanism to prevent autoimmune reactions is deletion of self-reactive 
lymphocytes and is called central tolerance, which occurs in the thymus during the 
maturation of the lymphocytes 111. The precursors of the T lymphocytes originate from the 
bone marrow. Then, they migrate to the thymus, where they will go through a complex 
process of maturation and differentiation to finally become functional T lymphocytes. This 
maturation is characterized by TCR formation and by exclusive expression of CD4 or CD8 
112. During the maturation process, the T cell rearrange randomly their TCR 113, creating 
many variants, which are useless since they are unable to recognize antigen-self-MHC with a 
high enough affinity. TCRs with too low affinity for self- MHC will die by neglect, and 
commit apoptosis. This process is called positive selection and it allows that only cells 
expressing a TCR that can interact with self-peptide–MHC complexes to differentiate further 
114.  
The hallmark of central tolerance is clonal deletion characterized by suicide of T-cell 
progenitors that have high affinity for self-antigens. Strongly self-reactive progenitors are 
under strict control and it is the moderately reactive progenitors that mature, populate the 
lymphoid organs and participate in immune responses to foreign antigens 111,115,116.  
Central tolerance is an efficient process, but some self-reactive cells may escape this control, 
in part because not all self-antigens are expressed at the primary site of lymphocyte 
development    or the affinity TCR-MHCII-peptide is too low 117,118. In addition, peripheral 
tolerance mechanisms exist, which renders these lymphocytes tolerant, when they first 
encounter their cognate self-antigen outside the thymus. 
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1.3.2. Peripheral tolerance 
Cells escaping central tolerance are kept under control by mechanisms of peripheral 
tolerance. Mature T cells that recognize self-antigens in peripheral tissues become incapable 
of subsequently respond to these antigens. The mechanisms of peripheral tolerance are: 
anergy, deletion, ignorance and Tregs. Anergy is characterized by the inability of a CD4 T 
cell to respond to stimulation. This state is induced when T cells are improperly activated for 
example without costimulation or with CTLA-4, which binds to B7 119,120. Anergy can be 
broken by addition of IL-2 in vitro. Immature DCs, which express a low level of costimulator 
molecules induce anergy 37. Deletion is another mechanism by which CD4 T cells repeatedly 
activated by a persistent antigen will die by apoptosis in a process called activation-induced 
cell death 121. 
In many cases, T cells simply ignore antigens present only within specialized organs. These T 
cells, even if of only low affinity for the antigen in question, could provoke autoimmunity if 
sufficient help is provided, for example, through localized production of IL-2 or through 
provision of cross-reactive help 122. Another efficient control is active suppression mediated 
by Tregs 123,124. 
 
1.3.2.1. T regulatory cells 
T cells with suppressive capacity were described first by Gershon in the early 1970s and were 
called suppressive cells 125,126. Several Treg subsets have been described and are involved in 
peripheral tolerance keeping the immune system under control. But they can roughly be 
divided into natural or inducible Tregs (iTregs). The natural Tregs cells or CD4+CD25+ T 
cells, which are characterized by high level of CD25 and FOXP3 expression, originate in the 
thymus but, importantly, they can also be generated in the periphery. The inducible Tregs 
including Tr1 and Th3 cells can be generated out of naïve cells and suppress target T cells (or 
responder cells) in a contact-independent manner by secretion of IL-10 127 and TGF-β 58,128. 
The Th3 cells are responsible for antigen tolerance induced, when the antigen is fed. 
Oral tolerance discovered by Wells in 1911 refers to the oral administration of protein 
antigens, which induces a state of systemic non-responsiveness specific for the fed antigen. 
This method of inducing immune non-responsiveness has been applied to the prevention and 
treatment of experimental animal models of experimental autoimmune encephalomyelitis 
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(EAE) 129,130, rheumatoid arthritis 131, insulin dependent diabetes mellitus 132,133, 
transplantation 134,135 and food allergy 136. Tolerance induction, in this model, is mediated by 
T cells. This has been shown in adoptive transfer experiments, in which T cells adoptively 
transferred from sensitized animal to naïve animal were preventing the disease. The Th3 cells 
were discovered originally using an oral tolerance model, in which SJL mice (susceptible to 
EAE) 137,138 were fed with myelin basic protein (MBP). MBP is a protein expressed in the 
central and peripheral nervous systems. It is recognized by autoreactive T cells, which 
destroy myelinated neurons leading to MS or EAE, MBP–specific TCR T cells are found in 
patients with MS. Tolerance induction was characterized by generation of antigen-specific 
cells producing high amount of TGF-β and lower amount of IL-4 and IL-10. Furthermore 
Th3 cells injected in mice at the time of immunization with MBP were protective against 
EAE development 139,140.  
Tr1 cells were generated upon repeated stimulations of naïve T cells with OVA and IL-10. 
These cells produce high amount of IL-10 with or without TGF-β. Tr1 cells proliferate poorly 
after polyclonal or Ag-specific activation in vitro and have suppressive capacity as 
demonstrated by adoptive transfer in a mice model of colitis 141. Il-10-secreting cells play an 
important role in allergies and transplantation 142,143. Non-allergics have a higher number and 
frequency of IL-10-secreting cells, which keep the immune reaction under control when 
exposed to the allergen compared to atopic patients 144. 
 
1.4. CD4+CD25+FOXP3+ T regulatory cells 
Among different types of Tregs, naturally arising CD4+CD25+ Treg cells are the best 
characterized and studied. These cells comprise 5-10% of CD4+ T cells in peripheral 
lymphoid organs and represent a unique T cell lineage that undergoes thymic selection and 
migrates to the periphery 145. Their relationship to the other subsets of regulatory cells is still 
not clear. Mature Treg cells can be identified by their constitutive expression of CD25, 
CTLA-4, PD-1, CD103, human leukocyte antigen-DR (HLA-DR), transferring receptor 
(CD71) and glucocorticoid-induced tumor necrosis factor receptor family-related receptor 
(GITR) 146-154. 
The CD4+CD25+ Treg cells have been identified by Sakaguchi in 1995 in experiments 
consisting in the depletion of CD4+CD25+ T cells in adult mice, which resulted in the 
development of various autoimmune conditions (thyroiditis, gastritis, insulitis, sialoadenitis, 
adrenalitis, oophoritis, glomerulonephritis, and polyarthritis).  Reconstitution of CD4+CD25+ 
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cells within a limited period after depletion prevented these autoimmune developments in a 
dose-dependent fashion, whereas the reconstitution several days later was far less efficient for 
the prevention of the autoimmune disease 155. As expected from these experiments, Treg cells 
play a major role in keeping the immune system under control and dysfunction have been 
found in many diseases ranging from autoimmunity, cancer to allergy and asthma. In 
autoimmune disease Treg cells are deficient 147,156-169 and restoration of CD4+CD25+ Treg 
could protect against the development of the disease 170. In allergies harmless antigens are 
recognized by T cells and trigger an immune response. Several studies have demonstrated a 
role for the CD4+CD25+ Tregs in regulating allergic disease. The T cells from healthy non-
allergic subjects do not proliferate when in contact with cows’milk antigen. However, 
depletion of CD4+CD25+ T cells resulted in T cell proliferation, suggesting that Tregs cells 
normally suppress the responses to dietary antigens 171. CD4+CD25+ are generated in the 
periphery of the transplant during organ transplantation 172 or GVHD 173,174 and can stop the 
rejection reaction induced by the foreign antigen. Therefore Tregs are promising targets to 
diminish the immune reaction induced in allergies, transplantation and autoimmune diseases. 
One approach to use Treg as therapeutic tool is to expand them in vitro, thereafter inject 
expanded cells back to the host 175,176. 
Although that a lack of suppression leads to deleterious immune response against harmless 
antigens, too much suppression obviously favors tumor growth and chronic infection. A 
higher frequency of Treg cells in peripheral blood was reported in patients with various 
cancer including breast cancer 177, colorectal cancer 178,179, oesophageal cancer 179, gastric 
cancer 179, hepatocellular carcinoma 180, leukaemia 181, lung cancer 182, lymphoma, melanoma 
183,184, ovarian cancer 185 and pancreatic cancer compared to healthy individual. It has been 
shown that regulatory cells are recruited or generated in the periphery of the tumor in a TGF-
β-mediated manner186. Tregs obviously actively suppress the immune response to the tumors 
and depletion of CD4+CD25+ T cells in mice, by in vivo injection of a depleting anti-CD25 
antibody (PC61) resulted in suppression of growth of the tumor 157,187,188. 
Tregs suppress proliferation and cytokine production from responder cell in a contact-
dependent mechanism, since suppression does not happen when a cytokine-permeable 
membrane separates the cells. Importantly, the presence of APCs is not required, as 
suppression occurs in APC-free cultures. Suppression requires activation of suppressor T 
cells by TCR ligands or antibodies to CD3 145. Interestingly, the cells are activated in an 
antigen-specific way, whereas suppression occurs in an antigen-non-specific-manner 171. 
Although the precise molecules involved in suppression are still unidentified a role has been 
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suggested for CTLA-4, GITR and membrane-bound TGF-β 189-191. However, the role of 
suppressive cytokines (IL-10 and TGF-β) is still unclear in the suppression mediated by 
CD4+CD25+ Tregs and has been challenged by the following studies: the addition of 
neutralizing antibodies that are specific for IL-10 or TGF-β does not reverse suppression, and 
CD25+ T cells from Il10 −/− mice are fully competent suppressors in vitro 192. Furthermore, 
CD4+ T cells from transgenic mice that express a dominant-negative form of the TGF-β 
receptor (TGFβRII) that cannot respond to TGF-β-derived signals 193 were fully suppressible. 
Finally, CD25+ T cells isolated from young TGF-β -/- mice 194 are fully competent 
suppressors when mixed with CD25− T cells from wild-type mice. Thus, the potential role of 
TGF-β in CD25+ T-cell-mediated suppression remains controversial. In addition Treg might 
use cytolytic activity against autologous CD4+ and CD8+ T cells, CD14+ monocytes, and 
dendritic cells in order to regulate suppression. Inducible Treg express granzyme B and 
activated CD4+CD25+ Tregs express granzyme A and small amounts of granzyme B. Both 
subtypes displayed perforin-dependent cytoxicity 195.  
In vitro studies showed that CD25+ suppressor T cells are anergic. They do not proliferate in 
culture, when stimulated with antibodies to CD3 or antigens unless supplemented with high 
doses of IL-2.  
 
1.4.1. Tregs of thymic origin 
A large part of CD4+CD25+ Treg cells originates from the thymus, since thymectomy before 
day 3 post-birth decreases the number of CD4+CD25+ and leads to autoimmunity 156. Other 
evidences about the thymus origin of Treg are coming from their TCR repertoire. Hsieh et al 
determined that the TCR repertoire of thymic Treg cells was diverse and was more similar to 
that of peripheral Treg cells than that of nonregulatory T cells. The finding indicates that 
thymic Treg cells make a substantial contribution to the peripheral Treg cell population 196. 
The mechanisms involved in thymic generation of CD4+CD25+ Tregs cells are poorly 
understood but it has been shown that thymocytes have already regulatory properties. A 
subset of CD25+ cells in the CD4 single positive thmyocyte compartments with suppressive 
capacity was discovered. After characterization in adoptive transfer models and in in vitro 
suppression assays in mice and human, it showed that functional Treg are generated in the 
thymus 157,197,198. The generation of CD4+CD25+ Treg cells requires MHC class II expression 
in the thymus, as does the generation of conventional CD4+ T cells.  However conventional 
CD4+ T cells require low-affinity peptide-MHC class II interactions for positive selection, 
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whereas Treg cells apparently require high-affinity peptide-MHC class II interactions with 
agonist peptides that otherwise induce negative selection 199. 
The expression of self-antigens in the thymus is important in efficient de novo generation of 
CD4+CD25+ thymocytes as shown by studies that high-affinity interactions with agonist 
ligands expressed in radioresistant tissue 200,201 and specifically in thymic epithelial cells 202, 
are necessary for generation of CD4+CD25+ suggesting that in fact CD4+CD25+ escape 
negative selection. This process requires CD28-dependent costimulation of developing 
thymocytes and particularly the Lck-binding motif in the CD28 cytosolic tail initiate the Treg 
cell differentiation program in developing thymocytes 203.  
A feature shared by Treg cells and T cells with autoimmune potential is the ability to 
recognize self-antigens. Treg cell recognition of self antigens was initially suggested after 
observations indicating that the presence of a particular organ was important for the 
maintenance of Treg cell-mediated tolerance to that organ 204 and nonregulatory T cells 
transduced with Treg cell-derived TCRs rapidly expand their populations in vivo and induce 
wasting disease in lymphopenic hosts 205.  
To address that issue, Hsieh examined the naturally arising polyclonal TCR repertoire in 
normal thymic and peripheral regulatory and nonregulatory T cells. This 'normal' set of TCRs 
was then compared to the TCR repertoires found in TCRs expressed by autoreactive T cells 
in Foxp3-/- mice, as the spontaneous autoimmunity in these mice results from their lack of 
Treg cells 206. No defect in negative selection was found in these mice, therefore the lack of a 
functional Foxp3 gene might allow autoreactive T cells, normally present in peripheral 
nonregulatory and regulatory T cell populations, to 'realize their pathogenic potential'. In 
agreement with that idea, activated but not naive T cells in Foxp3-/- mice often used TCRs 
found in the Treg cell TCR repertoire of normal mice. Thus, T cells expressing these self-
reactive TCRs are not eliminated but instead are likely to contribute to pathology associated 
with Foxp3 deficiency. Suggesting that many autoimmune T cells in the normal 
nonregulatory T cell population may share the TCR specificity of their naturally arising Treg 
cell chaperones 196,205,207. 
The maturation process of Tregs in the thymus may occur in the Hassall corpuscles, which 
express thymic stromal lymphopoietin (TSLP). Human TSLP activates thymic CD11c-
positive dendritic cells to express high levels of CD80 and CD86. These TSLP-conditioned 
dendritic cells are then able to induce the proliferation and differentiation of CD4+CD8-
CD25- thymic T cells into CD4+CD25+FOXP3+ Treg. This induction depends on peptide-
MHC-II interactions, and the presence of CD80 and CD86, as well as IL-2. CD25+CTLA4+ 
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regulatory T cells associate in the thymic medulla with activated or mature DCs and TSLP-
expressing Hassall's corpuscles, suggesting that Hassall's corpuscles have a critical role in 
DC-mediated secondary positive selection of medium-to-high affinity self-reactive T cells, 
leading to the generation of CD4+CD25+ Treg within the thymus 208. 
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Figure 4: Generation of Tregs in the thymus and periphery. Tregs have been described to 
originate both in the thymus and in the periphery. The Tregs originating from the thymus are called 
natural Tregs whereas the Tregs from the periphery are called adaptive or inducible. The inducible 
Tregs are divided into different subsets, according to their FOXP3 expression or mechanisms of 
suppression. The Tr1 mediate suppression by IL-10 secretion and the Th3 by TGF-β. 
 
1.4.2. Peripheral generation of CD4+CD25+FOXP3+ Tregs 
 
Intrathymic generation of Treg is not the only process of Treg development, importantly their 
generation by the conversion of CD4+CD25- into CD4+CD25+ with suppressive capacity has 
been demonstrated in the periphery in vivo under natural conditions, allowing efficient 
generation of Tregs with specificity to antigens, which are not present in the thymus. The 
potential of CD4+CD25- to become CD4+CD25+ was analyzed by Liang et al. in mice. 
CD4+CD25- T cells expressing a special marker were sorted and transferred into congenic 
mice. After six weeks 5-12 % of transferred CD4+CD25- converted to CD4+CD25+. 
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Converted CD4+CD25+ cells acquired Treg properties and phenotype, since they failed to 
proliferate after stimulation and could suppress proliferation of responder cells in vitro, and 
importantly also expressed high levels of Foxp3 mRNA. In addition, CD4+CD25- cells 
transferred into thymectomized congenic mice converted to CD4+CD25+ Treg cells, 
demonstrating that the thymus is not required for peripheral generation of Tregs. 
Costimulation, however, was necessary since CD4+CD25- cells transferred into B7-/- mice 
failed to convert into CD4+CD25+ cells that exhibit the regulatory phenotype. These results 
indicate that CD4+CD25- cells convert into CD4+CD25+ regulatory T cells spontaneously in 
vivo and suggest that this conversion process could contribute significantly to the 
maintenance of the peripheral CD4+CD25+ regulatory T cell population. 209,210.  
 
1.4.3. Cytokines involved in the generation and maintenance of Tregs 
Cytokines are not only necessary for the function of Tregs but also for their generation and 
maintenance. IL-2 and IL-15 are mandatory and are their principal growth factors. However, 
IL-7, which is required for the development, homeostatic proliferation and maintenance of T 
cells 211-214, does not act on Tregs 215,216. The IL-7Rα (CD127) is highly expressed by naïve T 
cells and thymocytes but is downregulated on Tregs and can be used in sorting strategies to 
isolate very pure Tregs population CD4+CD25+CD127- 217,218. TGF-β in addition to its many 
inhibitory effects on T effector cells has been shown to be important in the generation and 
homeostasis of Tregs. 
 
1.4.3.1. IL-2 
The constitutive high expression of the IL-2R α-chain suggests an important role for IL-2 in 
Treg generation and turn-over, accordingly patients receiving Il-2 therapy expand their Treg 
compartment 219. The analysis of IL-2 and CD25 deficiency in mice indicated that generation 
of functional Treg in thymus was independent on IL-2 signaling, but that IL-2 was essential 
for the survival of mature CD4+CD25+ Treg in the periphery 220,221 and may be essential for 
their function 222,223. Furthermore, lymphopenia seems to induce homeostatic growth of Tregs 
cells 224. IL-2 triggers the JAK-STAT-signaling cascade and directly modulates FOXP3 
expression. IL-2R signaling is primarily mediated through activation of JAK1 and JAK3 with 
subsequent phosphorylation and activation of STAT3 and STAT5 225. In vitro, IL-2 
selectively upregulated the expression of FOXP3 in purified CD4+CD25+ T cells but not in 
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CD4+CD25- cells. This regulation involved the binding of STAT3 and STAT5 proteins to a 
highly conserved STAT-binding site located in the first intron of the FOXP3 gene 226-228.  
Therefore immunosuppressive drugs targeting IL-2 signalling may influence Treg turnover. 
 
1.4.3.2. TGF-β  
TGF-β has not only been proposed to be an effector cytokine secreted by CD4+CD25+ 
mediating suppression. It has also been shown to play an important role in the induction of 
CD4+CD25+ Treg out of CD4+CD25- T cells in vitro and in vivo 229. The role of TGF-β was 
first discovered in mice 210 and later in human 64,230. TGF-β induces FOXP3 expression in 
TCR-stimulated T cells, as well as surface expression of CD25, HLA-DR, GITR, CD103 and 
intracellular CTLA-4 230. The generated cells are not only unresponsive to TCR stimulation, 
but produce also TGF-β and IL-10, however they do not produce Th1 nor Th2 cytokines. 
They are potent suppressors of proliferation and cytokine production in vitro. Tregs induced 
in vitro by TGF-β have been demonstrated to be suppressive in vivo in an OVA peptide 
transgenic adoptive transfer model as well as in a murine asthma model, in which TGF-β-
induced Treg transferred to mice protected against the house dust mite-induced allergic 
pathogenesis in the lungs 210. Although it is well accepted that TGF-β can induce 
CD4+CD25+FOXP3+ Tregs in vitro, its role in vivo is still controversial. TGF-β-treated mice 
increase the pool of Tregs, in several experimental systems, it is not always distinguhised 
between truly de novo generation and proliferation of preexisting Tregs. TGF-β is essential in 
expanding Tregs as shown by a transient pulse of TGF-β in the islets of the pancreas during 
the priming phase of diabetes. The frequency of CD4+CD25+FOXP3+ Tregs dramatically 
increased due to in situ expansion of Tregs 231. TGF-β1-/- mice develop severe 
autoimmunity. In these mice the Tregs develop normally in the thymus, but were found in a 
significantly reduced number in the periphery. The Foxp3 expression in the Treg is lower and 
cells are less suppressive. Further indicating that TGF-β signaling is essential in maintaining 
Treg in vivo 232. In addition transgenic mice overexpressing TGF-β under the control of the 
CD2 promoter show an increased frequency of Tregs in the periphery. TGF-β was also 
shown to enhance the conversion rate of CD4+CD25- T cells to Treg when cells are 
stimulated with subimmunogenic peptide 233 
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1.4.4. FOXP3 
FOXP3 was identified by positional cloning on the X-chromosome as the gene mutated in the 
scurfy mouse, characterized by wasting, exfoliative dermatitis, lymphadenopathy, 
hepatosplenomegaly, and the presence of autoantibodies. The mouse carrying the scurfy 
mutation leads to death at approximately 3 weeks of age from a massive lymphoproliferative 
disease, with peripheral lymphocyte levels up to 20-fold greater than normal mice only male 
are affected. The autoimmune disease is prevented by neonatal adoptive transfer of Tregs 
from wild-type mice to scurfy mice 234. In addition, the mice display anemia 235. The 
autoimmune-like disease in affected animals resembles knock-out mice for ctla-4 or tgf-b1 
genes 236,237.  
In human, mutations in FOXP3 gene are responsible for the immune dysregulation 
polyendocrinopathy enteropathy, X-linked syndrome (IPEX; also known as X-linked 
autoimmunity and allergic dysregulation syndrome, XLAAD). Patients with IPEX syndrome 
suffer from a neonatal onset of insulin-dependent diabetes, infections, enteropathy, 
thrombocytopenia and anemia, endocrinopathy, eczema and cachexia. Massive T-cell 
infiltration into the skin and gastrointestinal tract is also observed, as well as high serum 
levels of autoantibodies, which is indicative of autoimmune disease. Affected children also 
suffer from allergic manifestations including severe eczema, high IgE levels, eosinophilia and 
food allergies. The severe immune dysregulation observed in human and mice lacking 
functional FOXP3, indicates its important function in regulating the immune system. In fact, 
mice lacking FOXP3 (FOXP3-/-) also lack CD4+CD25+ Treg.  
Naïve CD4+CD25- T cells, retrovirally transfected with FOXP3 were acquiring a T regulatory 
phenotype. They were hyporesponsive to TCR stimulation anergic and were able to suppress 
proliferation of other cells. Foxp3-infected T cells could suppress in vivo the inflammation 
and the autoimmune disease in a model of IBD and autoimmune gastritis that can be induced 
in severe combined immunodeficiency (SCID) mice by the transfer of 
CD25+CD45RBhighCD4+  T cells from normal BALB/c mice and prevented by cotransfer of 
CD25+CD4+ TR cells 238,239. The Foxp3-transduced cells inhibited weight loss, diarrhea, and 
histological development of colitis and gastritis induced by the transfer of CD25-
CD45RBhighCD4+ cells as effectively as naturally occurring CD25+CD4+ Treg cells 
240.Underlying the decisive role of FOXP3 in T regulatory cells development or/and function 
in human and mice 241. 
These results are still controversial, particularly in human cells in which two isoforms of 
FOXP3 are found. Ectopic expression of the two FOXP3 isoforms in CD4+ cells resulted in 
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induction of hyporesponsiveness and suppression of IL-2 production, but the cells were only 
weak suppressors. These data indicate that in humans, overexpression of FOXP3 alone or 
together with FOXP3delta2 is not an effective method to generate potent suppressor T cells 
in vitro. And suggest that factors in addition to FOXP3 are required during the process of 
activation and/or differentiation for the development of Tregs 242. 
Using mice harboring a GFP-Foxp3 fusion protein-reporter knockin allele it has been shown 
that FOXP3 expression is restricted to a subset of αβ T cells, which are CD25+ but can also 
be CD25-. Importantly FOXP3 expression correlates with regulatory and suppressive 
function 243-245. FOXP3 is therefore seen as a lineage factor for commitment into Tregs. 
FOXP3 belongs to a large family of functionally diverse transcription factors based on its 
winged helix-forkhead DNA-binding domain (forkhead box(Fox)). These proteins have been 
classified into subfamilies (indicated by the letter after “FOX”) based on phylogenetic 
analysis of homology in the forkhead domain only, and each has been assigned a unique 
number (at the end of the name) 246. In addition to the C-terminal forkhead domain, FOXP3 
also contains a Cys2His2 zinc finger domain and a coiled-coil-leucine zipper motif. 
Homology among full-length human, mouse and rat FOXP3 is very high, suggesting a highly 
conserved function. Members of the Fox family are both transcriptional activators and 
transcriptional repressors. The ability of Foxp3 to act as a transcriptional repressor required 
the presence of the FKH domain of Foxp3. At present there is very little understanding of the 
function of FOXP3 at the molecular level. FOXP3 binds DNA, localizes to the nucleus and 
can act as a transcriptional repressor. In the Jurkat T cell leukemia cell line, it inhibits 
transcription mediated by the nuclear factor of activated T cells (NFAT) transcription factors, 
requiring the forkhead domain for both nuclear localization and DNA binding. FOXP3 can 
also form a complex with NFAT while competing with AP-1. And therefore an activating 
complex NFAT-AP1 is replaced by a repressive complex NFAT-FOXP3 247. In addition mice 
expressing a Foxp3 transgene were unable to produce IL-2, IL-4 or IFN-y following TCR-
mediated stimulation in vitro and showed a severely reduced ability to express cytokines in 
vivo following immunization 248,249.  
The Foxp3 transgenic mice also provided a model system for examining the in vivo 
consequences of Foxp3 expression. When bred into an otherwise wild-type background, 
resulted in a reduction in peripheral CD4+ and CD8+ T cell numbers 234. 
However thymic cellularity was unaffected, as was positive and negative selection. Thus, 
levels of Foxp3 determined the number of peripheral T cells, while having little effect on the 
number and differentiation of thymocytes 250. 
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1.5. Concluding remarks and aim of the study 
T cells with suppressive capacity have been identified in the 1970s. Due to difficulties in 
isolating and characterizing the cells enthusiasm dampened down and scepticism was 
growing. In 1995, Sakaguchi identified CD4+CD25+ T cell as potent regulators of the 
immune response, the field was thus, revitalized. Treg dysfunctions are found in many 
diseases bringing a new understanding of many pathogenesis. Therapies targeting Tregs are 
therefore very promising. CD25, the IL-2 receptor α chain, is not a reliable marker, since it is 
upregulated during activation of CD4+ T cells. Therefore the discovery of FOXP3, as a 
transcription factor expressed selectively in Tregs, was a great breakthrough in tolerance 
immunology. Although it is an intracellular protein, development of specific antibodies and 
transgenic animals allows analysis at the single cell level. A better knowledge of its gene 
expression regulation will give a better understanding of the Treg turnover. 
The aim of this thesis was to gain insight into the mechanisms involved in Treg generation. 
For this purpose we looked at the FOXP3 gene regulation, particularly we analyzed its 
promoter and identified molecular pathways involved in the induction and repression of 
FOXP3 expression. 
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2. Results 
2.1. Molecular mechanisms underlying FOXP3 induction in human 
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Abstract 
FOXP3 is playing an essential role for T regulatory cells (Tregs) and is involved in 
the molecular mechanisms controlling immune tolerance. Although the biological 
relevance of this transcription factor is well documented, the pathways responsible for 
its induction are still unclear. The current study reveals structure and function of the 
human FOXP3 promoter, revealing essential molecular mechanisms of its induction. 
The FOXP3 promoter was defined by RACE, cloned and functionally analyzed using 
reporter-gene constructs in primary human T-cells.  
The analysis revealed the basal, T-cell-specific promoter with a TATA and CAAT-
box 6000bp upstream the translation start site. The basal promoter contains six NFAT 
and AP-1 binding sites, which are positively regulating the transactivation of the 
FOXP3 promoter after triggering of the TCR. The chromatin region containing the 
FOXP3 promoter was bound by NFATc2 under these conditions. Furthermore, 
FOXP3 expression was observed following TCR engagement. Both promoter activity, 
mRNA and protein expression of T-cells were suppressed by addition of cyclosporin 
A (CsA). Taken together, this study reveals the structure of the human FOXP3 
promoter and provides new insights in mechanisms of addressing Treg inducing 
signals useful for promoting immune tolerance. Furthermore the study identifies 
essential, positive regulators of the FOXP3 gene and highlights CsA as an inhibitor of 
FOXP3 expression contrasting other immunosuppressants such as steroids or 
rapamycin. 
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Introduction. 
T cells play a key role in adaptive immunity and enable the immune system to 
develop specific immune responses. T cell activation is tightly regulated allowing 
responses against pathogens, while maintaining tolerance of harmless antigens. 
Disequilibrated immune tolerance causes autoimmune disease or allergy. Thus 
immune tolerance is an important mechanism that allows to distinguish between self 
and non-self 251,252. Regulatory T cells (Tregs) are critical regulators of immune 
tolerance and their suppressive control of effector T cells was observed in 
experimental systems 253 and human 144,254. Tregs are defined by their function, and 
express the transcription factor FOXP3 and/or suppressive cytokines (IL-10, TGF-β) 
as well as CTLA-4 and/or CD25 146,155,192,255,256. FOXP3 is a transcription factor, 
belonging to the forkhead family 257 and it has been shown that FOXP3, 
overexpressed in Jurkat cells, can act as a repressor of transcription of the IL-2 
promoter by competing with the binding of NFAT 258 or by directly interacting with 
NFAT or NFκB 259. The CD25+ Tregs express constitutively high amount of FOXP3 
and represent about 5-10% of the total CD4+ population. Despite the great relevance 
of these cells in immunology and clinical issues, the origin and pathways of Treg 
induction are still unclear. Interestingly it could be demonstrated that ectotrophic 
expression of FOXP3 in T cells was sufficient to restore autoimmune symptoms of 
mice depleted of CD25+ T cells 220,240. In fact genetic defects of the human ortholog 
causes the IPEX syndrome (immune dysregulation polyendocrinopathy enteropathy, 
X-linked) 257. Patients with IPEX syndrome suffer from a neonatal onset of insulin-
dependent diabetes, infections, enteropathy, thrombocytopenia and anemia, 
endocrinopathy, eczema and cachexia 260 and transgenic mice lacking FOXP3 are 
developing a severe autoimmune disease 248,250,261.   
These evidences indicate that FOXP3 is a gene, which is involved in the generation or 
maintenance of regulatory T cell phenotypes, which is essential for maintaining 
immune tolerance. Interestingly it has been shown that its expression can also be 
induced in the CD4+CD25- population by activation 63, corticosteroids 262, estrogen 263 
and TGF-β 264,265, suggesting that FOXP3 can be induced in peripheral T cells, which 
may become crucial for therapeutic interventions. We therefore investigated the 
FOXP3 promoter to systematically reveal signals inducing FOXP3 expression. 
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The 5’-flanking region of the human FOXP3 gene was cloned and the promoter 
activity was characterized in primary CD4+ T cells. The data demonstrate that the 
proximal promoter is localized in the region between –511/+176 bp upstream the 5’-
non-coding region and contains several common features of basal promoter such as a 
GC and a TATA box. Our results demonstrate that the promoter is inducible by 
activation in a NFAT-AP-1 dependent manner, which is inhibited by CsA. 
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Materials and Methods 
 
Localization of the human FOXP3 promoter by RACE 
The cDNA from CD4+ T-cells was amplified with the anchor primer and two nested 
antisense primers: RACE FOXP3 +987, RACE FOXP3 +521 (Table I) designed from 
the FOXP3 cDNA sequence. The PCR products were purified and cloned into pCR2.1 
vector (Invitrogen, Basel, Switzerland) for sequencing of the 5’cDNA ends.  
 
Cloning of the FOXP3 promoter, construction of deletion and mutant constructs 
The human FOXP3 promoter containing -1657 bp from TSS was amplified by PCR 
using FOXP3 promoter sequence specific primers from position -1657 to +176. The 
genomic DNA extracted from CD4+ T cells of a healthy donor was used as a 
template. The FOXP3 promoter amplicon was cloned into the pGL3 basic vector 
(Promega Biotech Inc., Madison, WI, USA) to generate the pGL3 FOXP3 –
1611/+176. Series of deletion constructs were generated. The PCR products were 
subcloned in the pGL3 basic vector. Site-directed mutagenesis in the FOXP3 
promoter region were introduced using the QuickChange kit (Stratagene, Amsterdam, 
The Netherlands), according to the manufacturer’s instructions. The constructs were 
generated by using pGL3 –511, -348, –307 or –211 as template. Primers which were 
utilized to generate the individual constructs are listed in Table I. 
 
Bioinformatics 
Genomic sequences spanning the 5’-UTR of the FOXP3 gene was analyzed using the 
alignment software m-Vista: http://www-gsd.lbl.gov/vista/VistaInput 266, allowing to 
identify conserved regions. Transcritption factor binding sites were identified using 
TESS (http://www.cbil.upenn.edu/cgi-bin/tess/tess33) and Genomatix 
(http://www.genomatix.de) program, which uses matrices of the Transfac database. 
 
Isolation of CD4+ T cells 
CD4+ T cells were isolated from blood of healthy volunteers using the anti-CD4 
magnetic beads (Dynal) as previously described 267. The purity of CD4+ T cells was 
initially tested by FACS and was ≥ 95%. 
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Flow cytometry 
For analysis of FOXP3 expression at the single-cell level, cells were first stained with 
the monoclonal antibody CD25 (Beckman & Coulter, Switzerland), after fixation and 
permeabilization, cells were incubated with phycoerythrin-conjugated monoclonal 
antibody PCH101 (anti-human FOXP3; eBioscience) based on the manufacturer's 
recommendations and subjected to FACS (EPICS XL-MCL, Beckman& Coulter). 
 
Transfections and reporter gene assays 
T cells were rested in serum-free AIM-V medium (Life Technologies, Basel, 
Switzerland) overnight. An amount of 3.5 µg of the FOXP3 promoter Luciferase 
reporter vector and 0.5 µg phRL-TK was added to 3 x106 CD4+ T cells resuspended in 
100 µL of NucleofectorTM solution (Amaxa Biosystems, Cologne, Germany) and 
electroporated using the U-15 program of the NucleofectorTM . After a 24 hour culture 
in serum-free conditions and stimuli as indicated in the figures, luciferase activity was 
measured, by the dual luciferase assay system (Promega Biotech Inc., Madison, WI, 
USA) according to the manufacturer’s instructions. Data were normalized by the 
activity of renilla luciferase. Hela, CHO and Jurkat were transfected using 
lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. 
 
Quantitative real-time PCR 
The PCR primers and probes detecting FOXP3 were designed based on the sequences 
reported in GenBank with the Primer Express software version 1.2 (Applied 
Biosystems) as follows: EF-1α forward primer and reverse primer as described 268, 
FOXP3 forward primer A 5` GAA ACAG CAC ATT CCC AGA GTT C 3`, FOXP3 
reverse primer A 5` ATG GCC CAG CGG ATG AG 3`. The prepared cDNAs were 
amplified using SYBR®-PCR mastermix (Applied Biosystems) according to the 
recommendations of the manufacturer in an ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems). Relative quantification and calculation of the range of 
confidence was performed using the comparative ΔΔCT method as described 269. All 
amplifications were carried out in triplicates. 
 
Western blotting 
For FOXP3 analysis on the protein level, 1x106 cells CD4+CD25- were lysed and 
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loaded next to a protein-mass ladder (Magicmark, Invitrogen) on a NuPAGE 4-12% 
bis-tris gel (Invitrogen). The proteins were electroblotted onto a PVDF membrane 
(Amersham Life Science, Dübendorf, Switzerland). After blocking the membranes 
were incubated with an 1:200 dilution of goat anti-FOXP3 in blocking buffer (Abcam, 
Hamburg, Germany) overnight at 4°C. The blots were developed using an anti-goat 
HRP labeled mab (Amersham Biosciences) and visualized with a LAS 1000 camera 
(Fuji, Urdorf, Switzerland). To confirm sample loading and transfer, membranes were 
incubated in stripping buffer and re-blocked for 1 h, then re-probed using anti-actin 
(C-2, Santa Cruz).  
 
Pull-down Assay 
CD4+ T cells were stimulated with PMA and ionomycin for 2 hours at 37°C. The cells 
were pelleted, resuspended in buffer C (20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, 1 mM DTT, protease inhibitors (Sigma, Buchs, 
Switzerland) and 0.1% NP-40) and lysed on ice for 15 min. Insoluble material was 
removed by centrifugation. The supernatant was diluted 1:3 with buffer D (as buffer 
C, but without NaCl). The lysates were incubated with 10 µg of poly(dI-dC; Sigma) 
and 70 µl of streptavidin-agarose (Amersham Biosciences) carrying biotinylated 
oligonucleotides, for 3 hours at 4 °C. The beads were washed twice with buffer C/D 
(1:3) and resuspended in DTT-containing loading buffer (NuPAGE; Invitrogen), 
heated to 70°C for 10 min and the eluants loaded next to a protein-mass ladder 
(Magicmark, Invitrogen) on a NuPAGE 4-12% bis-tris gel (Invitrogen). The proteins 
were electroblotted onto a PVDF membrane (Amersham Life Science, Dübendorf, 
Switzerland) and detected using an anti-NFATc mab (Santa Crusz). The blots were 
developed as described above. Accumulated signals were analyzed using AIDA 
software (Raytest, Urdorf, Switzerland). 
 
Electrophoretic mobility shift assay (EMSA) 
EMSAs were performed as previously described 270. Nuclear extracts of CD4+ T cells 
were prepared as described.  Briefly, the cells were treated with a hyposmotic buffer, 
containing 10mM KCl, 1mM DTT, 0.5 mM EDTA, 10 mM HEPES pH 7.9 (all 
Sigma) and a mix of protease inhibitors (Complete™; Boehringer Mannheim, 
Mannheim, Germany), followed by addition of NP-40 (Sigma) to a 1% final 
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concentration. Nuclei were pelleted by a brief spin in a microcentrifuge and washed 
once with the buffer described above. Nuclei were lysed in 50 µl of a high-salt buffer 
containing 400mM NaCL, 50mM DTT, 20 mM HEPES, 0.5 mM EDTA and a mix of 
protease inhibitors (Complete™, Boehringer Mannheim, Mannheim, Germany). The 
nuclear debris of this lysate was removed by centrifugation at 4°C and the supernatant 
stored in a fresh tube at -70°C. Nuclear extracts were controlled for equal protein 
content by a protein assay as described by the manufacturer (Biorad, Hercules, CA, 
USA). 
Nuclear extracts were incubated with annealed oligonucleotides (Table I), which 
correspond to the FOXP3 promoter sequences as indicated in the figures. The two 
strands of the oligonucleotides first labeled with 32P-γ-ATP using the T4 Kinase (Life 
Technologies). Subsequently, the oligonucleotides were separated from free 32P-γ-
ATP by running the labeling mix over a chromaspin-10 column (Clontech, Palo Alto, 
CA). Following annealing, single stranded oligonucleotides were eliminated by gel-
purification of the column eluate on a 20% polyacrylamide gel. The eluted probe was 
precipitated and the binding reactions for the TATA-site were carried out for 30 min 
at RT with 2 µg of NE in 10 mM HEPES (pH 7.9), 10% glycerol, 1 mM EDTA, 1 
mM DTT, 100 mM KCl, 0,5 ug of poly(dI-dC), 1 mM PMSF and 30 000 cpm of 
probe. For the GC-box, 3 µg of NE were incubated as previously described in 271). 
The reaction was incubated for 10 min. at room temperature and loaded on a 5% non-
denaturating PAA gel. Following electrophoresis, the gel was dried, subjected to 
autoradiography and phosphoimaging.  
 
Chromatin immunoprecipitation (ChIP) assay 
ChIP assay was performed chromatin Immunoprecipitation (ChIP) Assay Kit 
following the recommandations of the supplier (Upstate Biotechnology, Lake Placid, 
NY, USA). For precipitation a polyclonal Ab against acetylated histone H4 was used 
along with an isotype matched rabbit IgG control. The PCR addressed for the FOXP3 
promoter region -246 to -511 and was performed using the following primers: 5’-
GTG CCC TTT ACG AGT CAT CTG-3’ and 5’-GTG CCC TTT ACG AGT CAT 
CTG-3’. The PCR products were visualized using an ethidium bromide gel. For ChIP 
assay addressing the NFAT binding to the chromatin an anti-NFATc2 (4G6-G5, 
Santa-Cruz Biotechnology, Santa Cruz, CA, USA) was used and primer addressing 
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the FOXP3 promoter region –1540 to -1470 to the following primer were used 5’-
TTT GCA GGG TGC TGG GA-3’ and 5’-GTA GAC CAG CCC CCA GGG-3’ and 
qRT- PCR was performed. 
 
FACS-sorting of CD4+CD25+ 
PBMC were isolated from Buffy coat by density gradient centrifugation over 
Ficoll/Hypaque. Cells were stained with PE-anti-CD25 and anti-PE magnetic beads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) and CD25+ cells were enriched using 
the Midi-MACS system (Miltenyi Biotec). CD25-enriched or -depleted cell 
populations were stained with FITC-anti-CD4 and sorted into CD4+CD25– and 
CD4+CD25high on a FACStar Plus (BD Biosciences).  
 
Suppression assay  
Samples in triplicate, containing 5 x 104 CD4+CD25- and 1 x104 of preactivated or 
resting CD4+CD25+T cells per well were incubated in 96 round-bottom-plates, which 
were previously coated with 1µg/ml antiCD3 mab or a matched isotype control. Cells 
were cultured for 4 days, pulsed for the last 10 h with 1 µCi [3H]-thymidine 
(Hartmann, Braunschweig, Germany) and harvested on glass fiber filters using an 
automated multisample harvester (LKB, Pharmacia-Wallac, Turku, Finland).  Filters 
were transferred in sample bags with liquid scintillation fluid and analyzed using a β-
scintillation counter (Pharmacia-Wallac).Round-bottom 96-well plates were coated 
with 1 µg/µl anti-CD3 for 1 hour at 37 °C and subsequently washed with PBS. 
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Results. 
Localization of the FOXP3 promoter in human CD4+ T cells 
To map the 5’ end of the human FOXP3 gene, 5’-RACE was performed, using 
nested-PCR. The first primer was located in exon 11 and the second in exon 6 of the 
FOXP3 gene. The mRNA was isolated from CD4+ T cells of a healthy donor, reverse-
transcribed and used as template for 5’-RACE. Sequence analysis of 11 clones 
revealed that the transcription start site (TSS) is located 6211 bp upstream of the 
translation start site. The UTR is interrupted by an intron zero of 6011 bp. An 
alignment of the sequences of human, mouse and rat FOXP3 gene was performed and 
several conserved regions (Figure 5A) were identified including 11 exons (Figur 5A, 
dark blue) and some conserved non-coding sequences (Figure 5A, red, CNS). 
Interestingly the region preceding the UTR is highly conserved (Figure 5A and Figure 
5B) and contains several transcription factor binding sites. On the basis of these sites, 
a putative promoter scheme was generated and tested in the following experiments 
(Figure 5C). 
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Figure 5: Human, mouse and rat alignment of the FOXP3 core promoter. (A) m-Vista 
alignment of Human/mouse genomic sequences (human accession number AF235097, mouse 
accession number AF277994). m-Vista criteria which were applied require 75 % identity for 
at least 100 bp length. The conserved regions are in red, the exons in dark blue and the UTR 
in light blue. (B) Sequence conservation of the human (top: GenBank accession number 
AF235097), mouse (middle: accession number AF277994) and rat (bottom: GenBank 
accession number NW_048035). The transcription start site (TSS) is indicated by a broken 
arrow. Transcription factor binding to the regions of interest are indicated (factor name above 
and position below), (C) Scheme of the 5’UTR region of the human FOXP3 gene, indicating 
the sites analyzed in this study. 
 
Chromatin structure 
Since FOXP3 is specifically expressed in T cells, we analyzed whether chromatin in 
the area of the putative promoter is accessible to the transcriptional machinery in T 
cells by chromatin co-immunoprecipitation (ChIP). Histone H4 hyperacetylation 
(H4ac) is a typical feature of active transcription 272, we therefore analyzed chromatin 
hyperacetylation of the FOXP3 promoter by comparing cells of lymphoid and non-
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lymphoid origin as well as T cells characterized by low or high FOXP3 expression. T 
cells were depleted of CD25+ and intracellular FACS staining revealed that FOXP3 
expression was virtually absent in the remaining cells (0.4%; figure 6A). The 
frequency of FOXP3+ T cells increased following T cell activation predominantly in 
the CD25+ subset (11.1 % after 72h; figure 6A). It occurred possible that activation-
induced FOXP3+ T cells expand from the 0.4% of CD25-FOXP3+ T cells, however on 
the basis of known T cell division kinetics (doubling maximally in 48h), the FOXP3 
expression must predominantly arise from the FOXP3- T cells. We demonstrated that 
histone hyperacetylation is detectable in CD4+ T cells, particularly in activated or 
FACS-sorted CD25+high Treg cells, but absent in HELA and Jurkat cells. Lower levels 
were observed in resting CD4+CD25- and CD4+CD45RA+ T cells (figure 6B), 
showing that the FOXP3 promoter region is in an open conformation and accessible 
to the transcription machinery in the CD4+CD25- cells, and that activation might play 
an important role in mobilizing the chromatin structure. The acetylation levels 
correspond to the FOXP3 mRNA expression levels of these cells (figure 6C). 
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Figure 6: Chromatin configuration of FOXP3. (A) FACS staining indicating FOXP3 
expression in CD4+CD25- T cells. Representative of two independent experiments. (B) The 
acetylation status of histone H4 in the nucleosomes associated with the FOXP3 core promoter 
region was assessed by ChIP assay in Jurkat, Hela and CD4+CD25- (resting and activated), 
and cells. Cells were lysed, and proteins were cross-linked with formaldehyde and 
immunoprecipitated with Ab to acetyled histone H4 (anti-acetyl H4) or control Ab (rabbit 
IgG). Shown is the, PCR for the FOXP3 gene after reversing the cross-linking. The “input” 
represents PCR amplification of the total sample which was not subjected to any 
precipitation. Results are representative of three independent experiments. (C) expression 
level of FOXP3 mRNA measured by RT-PCR. Bars show the mean ± SD of three 
independent experiments. 
 
The FOXP3 promoter region contains cell-specific activity 
The chromatin accessible region described above was functionally investigated for 
transactivational activity. To identify potential regulatory elements in the 5’-flanking 
region of the human FOXP3 gene, a serie of promoter-luciferase (LUC) 5’-deletion 
constructs were generated to test whether the FOXP3 promoter fragment also reflects 
cell-specificity. We transfected the identical constructs into cells of lymphoid and 
non-lymphoid origin that do not express FOXP3. High transactivation was observed 
in primary CD4+ T cells, whereas no activity was detected in Hela, CHO (data not 
shown) nor Jurkat cells independently of the promoter-fragment size (Figure 7). The 
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longest construct was designed from position –1657 to +176 and displayed a promoter 
activity in CD4+ T cells 3-fold higher than that of the control plasmid, pGL3 Basic 
(Figure 3). We designed 5’-deletions (-1210, - 511, -465, -423, -348, -307, –211 and -
90) in order to identify the proximalpromoter, which we could localize in a fragment 
of –511 bp from transcription start site. The –511/+176 region is highly conserved 
between human, mice and rat (Figure 5A + 5B). A 6.8-fold increase in luciferase 
activity was measurable with the fragment of –511/+176 compared to pGL3 basic 
vector. In contrast the smaller constructs (–307, -211 or -90/+176) show lower 
luciferase activity. Although the construct –307/+176 shows low activity, it is 
essential for the activity of the –511/+176, since a deletion of –245 to + 176 region 
out of –511 (-511/-245 construct) shows no activity in CD4+ T cells (Figure 7). Thus 
the construct –511/+176 showed the most prominent reporter activities, whereas 
larger fragments didn’t show any significant increase in activity over the –511/+176 
construct. These results together with the open chromatin configuration suggest, that 
the first 500 bp of basal FOXP3 promoter confer cell- specificity and transactivation. 
Having demonstrated that the promoter is active in CD4+ T cells we performed site-
directed mutagenesis to further characterize the promoter. 
 
 
Figure 7: The putative FOXP3 promoter is tissue specific. T cells, Jurkat and Hela cells 
were transfected with empty vector or vector containing the putative FOXP3 promoter 
region. Bars show the mean ± SD of arbitrary light units normalized for renilla luciferase of 
experiments performed with 6 independent donors (CD4+ T cells) or 6 independent 
experiments (in the case of Jurkat and Hela cells; samples were measured as triplets). 
 
 
 
 49 
Basal transcriptional elements are located in the core promoter 
To further investigate the functionality of the basal FOXP3 promoter located within 
the first 500 bp, we investigated binding sites characteristic for eukaryotic promoters. 
Putative Transcription factors binding sites were identified using TESS and 
GENOMATIX programs. In fact, several common features of eukaryotic core 
promoters such as the TATA, GC and CAAT boxes were identified. The TATA box 
(TATAAAA) is located –44 bp upstream of the transcription start site. This sequence 
is conserved between human, mouse and rat (Figure 5A). Since the TATA box is an 
important feature of eukaryotic promoters and is generally located -30 to -25 bp 
upstream the TSS, we investigated the element using site-directed mutagenesis of the 
fragment –211/+176 (TATAAAAG was mutated to TcTcgAAGC) and could 
demonstrate that the mutations, which eliminate TATA-binding sites dramatically 
reduce by 47.64 %; (Figure 8A) reporter activity. EMSA of the TATA box sequence 
of the FOXP3 promoter (TTA GAA GAG ACT CGG TAT AAA AGC AAA GTT 
GTT TT) bound by nuclear extracts from CD4+ T cells confirmed that nuclear 
proteins are binding to this promoter element. Only one complex could be detected, 
which could be competed by pre-incubation with unlabelled oligonucleotides specific 
for TATA box consensus sequence (GCA GAG CAT ATA AAA TGA GGT AGG 
A), which abolished in a dose-dependent manner the formation of the complex 
(Figure 8B).  
The GC box is another basic element of eukaryotic promoters, which is located 138 
bp upstream the TSS. A site-specific mutation (GC Sp1 - 142) was introduced to 
destroy transcription factor binding site into the–307/+176 fragment and luciferase 
assays were carried out. The mutation in the GC box decreased transactivational 
activity by 42,84 % (Figure 4C). The GC-box is known to be bound by Sp 
transcription factor family members. Sp1 acts as a potent activator and Sp3 can act as 
an activator or a suppressor, possibly by competing with Sp1 for the binding. Nuclear 
extracts from CD4+ T cell formed two specific complexes (Figure 8D), which were 
dose-dependently competed by the addition of specific Sp1-binding oligonucleotides 
at a 10 x and 100 x molar excess (ATT CGA TCG GGG CGG GGC GAG C) but not 
by mutated Sp1 oligonucleotides (ATT CGA TCG GTT CGG GGC GAG C). The 
addition of an antiserum against Sp1 shifted a band on the EMSA and the remaining 
complex I or II migrate slightly faster, indicating that the complex becomes smaller. 
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Similar observations were made using an anti-Sp3 antiserum, demonstrating that Sp1 
and Sp3 are binding to this sequence. Of note, the GC-box sequence can be bound 
also by other factors, which explains the binding of slightly faster migrating 
complexes upon addition of anti-SP-1 & 3 antibodies (lane 7-9; 273). Furthermore the 
CAAT-box was analyzed and mutated as described for the TATA and GC box. The 
mutation in the CAAT also reduced the luciferase activity of the -307/+176 fragment 
(data not shown). 
 
Figure 8: Basal elements of the human FOXP3 promoter. (A) The human FOXP3 contains 
functional TATA box and GC box. The region –211/+176, which contains the TATA box, 
was mutated in the pGL3 FOXP3 –211/+176. The mutated TATA box transfected into CD4+ 
T cells and the luciferase activity was measured. The effect of mutagenesis is shown as 
percent relative to wild-type pGL3 FOXP3 –211/+176. Results are given as the mean ± SEM 
of three independent experiments in triplicate. (B) Binding of specific nuclear factors to the 
TATA box. EMSA of the region –60 to –14 region of the FOXP3 gene promoter is shown. 
The competition experiments were performed by preincubating nuclear extracts with 10- and 
100-fold excess of TATA oligonucleotides (lanes 3-4). The region –307/+176 which contains 
the GC box was mutated in the pGL3 FOXP3 –307/+176. (C) The mutated GC box was 
transfected into CD4+ T cells and the luciferase activity was measured. Effect of mutagenesis 
is shown as percent relative to wild-type pGL3 FOXP3 –307/+176. Results are shown as the 
mean ± SEM of three independent experiments performed in triplicate. (D) Binding of 
specific nuclear factors to the GC box is demonstrated by EMSA of the –124 to –173 region 
of the FOXP3 gene promoter. The competition experiments were performed by preincubating 
nuclear extracts with 10- and 100-fold excess of Sp1 oligonuclotides (lanes 3-4) or mutated 
Sp1 oligonucleotides (lanes 5-6). The supershift assays were performed with antiserum 
against Sp1 protein (Sp1 Ab; lane 7), Sp3 protein (Sp3 Ab, lane 8), Sp1 and Sp3 proteins 
(Sp1 + Sp3 Abs; lane 9). Supershifted bands are observed in lanes 7-9 along with an 
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increased mobility of the remaining bands carrying unidentified factors, since the GC-box is 
bound by multiple factors. 
 
Regulation of FOXP3 expression in the CD4+CD25- cells by activation of the T cell 
receptor  
The experiments showed that the promoter construct was active in lymphocytes and 
contains basic elements like a TATA and a GC box. Since T cell activation is 
important for regulation of immune-relevant genes, we investigated, whether FOXP3 
mRNA and FOXP3 promoter fragments respond to T cell activation. FOXP3 mRNA 
can be induced (18.8-fold at 24h, 30.4-fold at 48h and 11.7-fold at 72h; Figure 9A) in 
the CD4+CD25- following T cell activation. Resting CD4+CD25+ were used as a 
control. Of note, FOXP3 expression in resting CD4+CD25+ T cells was 80-fold higher 
than in CD4+CD25- cells and could just slightly be increased by activation (1.9-fold, 
Figure 8 B). In analogy to upregulated FOXP3 mRNA, T cell activation also induced 
FOXP3 reporter activity in the CD4+CD25- cell fraction. The smaller fragments and 
empty vector were only slightly responsive to activation in contrast to the fragments 
starting from -348/+176, which were strongly induced about 80-fold compared to the 
empty vector or 10-fold compared to the corresponding unstimulated cells (Figure 
9B). 
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Figure 9: FOXP3 is upregulated by TCR crosslinking. (A) CD4+CD25- T cells were 
stimulated with anti-CD3 and anti-CD28, and the FOXP3 mRNA level was measured by real-
time PCR. Bars show the mean ± SD of 3 independent experiments. (B) The FOXP3 
promoter can be activated by TCR cross-linking. CD4+CD25- T cells were co-transfected with 
a renilla luciferase vector plus the luciferase vector containing the putative promoter region 
and were cultured in medium or in medium containing PMA and ionomycin. Results given 
are the mean ± SD of luciferase light units normalized for renilla luciferase of the same 
sample. Results are representative of 3 independent experiments. 
 
 
Cyclosporin A inhibits FOXP3 expression in human CD4+CD25- T cells 
We identified NFAT and AP-1 transcription factors binding sites located in the region 
between -348 and -511, which are known to be involved in T cell activation (Figure 
5B). NFAT is activated by the Ca++-calcineurin pathway and blocked by the 
immunosuppressive drug CsA. Therefore we analyzed the effect of CsA on the 
induction of FOXP3 mRNA and promoter activity. CD4+CD25- T cells were activated 
in the presence or absence of CsA and the mRNA was quantified after 24, 48 and 72 
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hours. The FOXP3 mRNA was potently inhibited by CsA, but not by MAPK 
inhibitors (Figure 10A). CsA inhibition of FOXP3 mRNA induction was maintained 
throughout the 72 hours time course (Figure 10B), while cell viability was maintained 
(data not shown). The CsA sensitivity of FOXP3 was confirmed at the protein level 
(Figure 10C). FOXP3 promoter fragments, which responded to activation, were 
potently inhibited by CsA. This indicates that the calcineurin-dependent NFAT 
mobilization plays a crucial role in the transactivation of the FOXP3 promoter (Figure 
10D). 
 
Figure 10: CsA inhibits FOXP3 induction in the CD4+CD25- T cells. (A) CD4+CD25- T 
cells were activated with anti-CD3 and anti-CD28 with CsA and different MAPK inhibitors. 
CsA potently inhibits FOXP3 induction. Bars show the mean ± SD of 3 independent 
experiments. (B) CD4+CD25- T cells were activated with anti-CD3 and anti-CD28 with CsA, 
cells were harvested at different time points as indicated in the figure. Bars show the mean ± 
SD of 3 independent experiments. (C) Western blot analysis of FOXP3 in CD4+CD25- T 
cells after activation with anti-CD3 and anti-CD28 and with treatment with CsA (1 µM). Two 
independent experiments were done with similar results. (D) CD4+CD25- T cells were 
transfected with the FOXP3 promoter constructs annd activated with PMA and ionomycin 
and treated or not with CsA.  
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NFAT and AP-1 are postive transactivators of FOXP3 
Since the construct -348 was the shortest construct showing TCR responsiveness. We 
mutated the AP-1 binding sites, in the construct -348. Mutation of the AP-1 site at 
position -306, which is closest to the TSS has only a weak effect on promoter activity 
(Figure 11). In contrast, mutation of the AP-1 site located -324 strongly reduced the 
transactivational activity of the promoter (3-fold; Figure 11). The background was 
also reduced suggesting that those factors play an important role in the constitutive 
promoter activity.  
 
 
Figure 11: The AP-1 sites of the FOXP3 promoter have transactivatory activity. 
CD4+CD25- T cells were transfected with construct containing AP-1 mutations and activated 
with PMA and ionomycin. AP-1 mutations decrease promoter activity, as well as its induction 
by activation. Bars show the mean ± SD of 3 independent experiments. 
 
Mutations of the NFAT and AP-1 sites in the constructs -511 had a dramatic effect on 
the basal activity and inducibility by T cell activation (Figure 12A). Loss of the 
NFAT-490 and -328 in the construct -511 decreased the activity by 38 % and 
activation induces only 3 times instead of 4 times in the wild-type. Loss of the NFAT 
binding site –383 and AP-1 -476 decreases the activity by 55 % and the induction 
following activation was only of 2.2-fold (Figure 12A). The binding of NFATc2 to 
the NFAT sites on -490 and –328 was proven by pull-down assay, using cells lysates 
of activated CD4+ T cells. NFATc2 was bound to the FOXP3 promoter 
oligonucleotides used for precipitation, but it was not precipitated by the mutated 
version (Figure 12B) or by the wildtype oligonucleotides competed by the excess of a 
NFAT consensus oligonucleotides (data not shown). To verify whether NFAT binds 
the FOXP3 promoter area on the chromatin under natural conditions, we performed 
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ChIP analysis. Starting from 2 hours after activation of CD4+ T cells with anti-CD3 
and anti-CD28 the binding of NFATc2 could be showed and was maximal after 5 
hours and decreases thereafter (Figure 12D). Overexpression of NFATc2 dramatically 
increased promoter activity of the -511 construct (3-fold, relative to the empty 
pcDNA3 vector), which could be further increased by activation (6.5-fold; Figure 
12E). The overexpression of NFATc2 had only a minor influence on the activity of 
the -90/+176 construct used as a control. 
 
 
Figure 12: NFATc2 regulates human FOXP3 promoter activity in CD4+CD25- T cells. 
(A) Mutation of NFAT sites decrease promoter activity as well as its induction by activation 
by PMA and Ionomycin. Bars show the mean ± SD of 3 independent experiments. B) Nuclear 
extracts were prepared from CD4+ T cells activated 2 hours with PMA and ionomycin. 
Biotinylated NFAT-376 and NFAT-328 oligonucleotides were absorbed by 
streptavidinagarose beads and then incubated with the nuclear extracts. Then the amounts of 
NFATC2 protein in the precipitates were assessed by immunoblotting with anti-NFATC2 
mAb. Total nuclear extracts were also run as controls. Two independent experiments were 
done with similar results. (D) CD4+CD25- T cells were activated using anti-CD3 and anti-
CD28 and analyzed by ChIP for NFAT binding to the FOXP3 promoter. Quantitative 
fluorogenic PCR was performed. Data are expressed as the ratio of immuoprecipiated to input 
sequence and are mean of ± S.D. of two separate experiments. (E) Overexpression of 
CD4+CD25- cells with NFATc2 with the 511 FOXP3 promoter construct increase the 
luciferase activity of  the FOXP3 promoter constructs. NFATc2 could not further increase the 
–90 lucierase activity. Results shown are the mean ± S.D. of 1 experiment performed in 
triplicate. Two independent experiments were done with similar results. 
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Regulation of FOXP3 in CD4+CD25+ Tregs 
It is known that overexpression of FOXP3 is sufficient to induce a Treg phenotype, 
however the significance of FOXP3 regulation in already existing T cells is not clear. 
We therefore investigated whether activation has any effect on FOXP3 expression in 
Tregs. We activated FACS-sorted CD4+CD25+ Tregs or CD4+CD25- effector T cells 
(Figure 13A) with plate-bound anti-CD3 and anti-CD28. After 3 days the cells were 
harvested and FOXP3 mRNA was measured by realtime-PCR. Resting CD4+CD25+ 
expressed about 90-fold more FOXP3 than CD4+CD25- cells. Activation induced 
expression of FOXP3 mRNA by only 1.9-fold (Figure 13A), in contrast to 20-fold 
CD4+CD25- cells (Figure 13B). In order to test whether this increase has a functional 
effect on Tregs function, we compared the suppressive capacity of unstimulated to 
preactivated Tregs. Although FOXP3 expression did only marginally increase (1.9-
fold), the activation dramatically increased the suppressive capacity of Tregs (Figure 
13C). However when Tregs were preactivated during 2 days in the presence of CsA, 
which was washed away before the cells were used in the suppression assay, the 
suppressive capacity was only marginally reduced (Figure 13C). Thus NFAT is 
important for FOXP3 induction, mediating regulatory differentiation, but does not 
affect the suppression of already existing Tregs, although activation potentates 
suppressive capacity.  
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Figure 13: Activation does not induce FOXP3 expression in pre-existing Tregs. (A) 
CD4+CD25high were FACS-sorted using the shown gates. (B) FACS-sorted CD4+CD25+ 
Tregs were activated with anti-CD3 and anti-CD28 during 3 days and treated or not with CsA 
(1 µM). The cells were harvested for mRNA extraction. The percentage was calculated on the 
basis of the ΔΔCt method. Bars, 95% confidence interval calculated on the basis of deviation 
of EF-1 and FOXP3 expression. The results shown are the mean ± S.D. of three independent 
experiments. (C) Activation dramatically increases CD4+CD25+ Tregs suppressive capacity, 
CsA couldn’t avoid this increase in the suppressive capacity. CD4+CD25+ Tregs were 
preactivated during 2 days in presence or absence of CsA. After washing the cells 3 times, 
their suppressive capacity on responder CD4+CD25- was tested. 10 x 104 CD4+CD25+ Tregs 
were added to 5 x 104 CD4+CD25-. The results shown are the mean ± S.D. of three 
independent experiments.
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Discussion 
In the present study we describe the localization and structure of the human FOXP3 
promoter, as well as elements, that are essential for its induction in T cells. 
The FOXP3 promoter is located -6221 bp upstream of the translation start site and the 
5’UTR is interrupted by a 6000 bp intron, which contains a splice donor site at the 5’ 
end and a splice acceptor site at the 3’ end, 22 bp upstream of the translation start site. 
The promoter is highly conserved between human, mouse and rat. The mRNA 
sequence published in the present study confirms the transcription start site and the 
location of the intron “0” of the reference sequence (NM_014009). 
The chromatin accessibility is a key mechanism of gene regulation and has been 
shown to be essential for many genes during T cell differentiation like IL-4 and IFN-γ 
109,274,275. FOXP3 has been proposed to be a lineage-specific factor for Tregs and 
therefore the chromatin structure may be an important aspect of FOXP3 regulation 
244,276. FOXP3 was accessible in resting and activated CD4+CD25- T cells, 
CD4+CD45RA and CD4+CD25+ but not in Jurkat and Hela cells, corresponding to 
their FOXP3 mRNA expression 254. Thus chromatin remodeling may contribute to the 
cell-specific expression of FOXP3, controlling the access of the transcriptional 
machinery to the promoter. The CD4+CD25- population showed an open chromatin 
conformation of FOXP3 gene, which was further increased by activation. The non-
repressive chromatin configuration may therefore allow CD4+CD25- T cells to 
acquire a regulatory phenotype upon activation with the appropriate key of 
transcription factors.  
In order to identify this set of transcription factors we analyzed the 1.6-kbp region 
upstream of the TSS. This region showed promoter activity, when cloned in front of a 
luciferase reporter gene and transfected into primary CD4+ T cells. In contrast, Hela 
and CHO cells did not show any promoter activity. Thus FOXP3 cell-specificity is 
regulated not only at the chromatin, but also on transcription level. The serial deletion 
constructs revealed that a fragment of 348 bp contained the minimal promoter 
necessary for the induction of the gene. The deletion of 245 bp upstream of the TSS 
totally abrogated the promoter activity, indicating that this area contains the core 
promoter. The current data show that the specific mutation of the TATA (-34), the GC 
(-138) and CAAT boxes (-218), reduce activity of the core promoter. Furthermore, we 
demonstrate that the GC box is in fact bound by Sp1 and Sp3. Since these factors are 
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characteristic for eukaryotic promoters 277, these data confirm the location of the 
FOXP3 promoter. 
On the basis of these results we analyzed inducible elements upstream of this area. 
We demonstrate that FOXP3 expression is induced following TCR engagement in 
CD4+CD25- T cells. Activation of CD4+CD25- T cells with anti-CD3 or PMA and 
ionomycin induced FOXP3 promoter activity in the -511 reporter gene. This result 
shows that TCR-engagement acts directly on the FOXP3 promoter and confirms 
previous studies 63 showing that in vitro activation of CD4+CD25- cells was sufficient 
to generate cells expressing FOXP3, which have suppressive capacity. In fact, 
exposure to an antigen 278, TGF-β 210,230,265, estrogen 279,280 or glucocorticoids 262 
along with T cell activation can induces FOXP3 in CD4+CD25- T cells. Therefore, 
activation seems to be a key event in the generation of Tregs, as it was previously 
shown to be essential in the differentiation process of Th1 and Th2 cells 281-283.  
We narrowed down the activation dependence to the minimal FOXP3 promoter (-
348), whereas the fragment that is just 41 bp shorter does not show any induction. 
Therefore the activation-responsive element of the FOXP3 promoter is located 
between -511 and -307. NFAT and AP-1 are well known mediators of T cell 
activation and are clustered in this region. Mutations disrupting the NFAT and AP-1 
binding sites decreased the luciferase activity, revealing their role in the 
transactivation of the FOXP3 promoter. The activation of the FOXP3 gene is 
mediated by at least three NFAT sites, which we demonstrated to be bound by 
NFATc2 and three AP-1 sites, in proximity of NFAT sites. Those transcription factors 
often cooperate to induce cytokine gene expression and are forming complexes as in 
the promoter of IL-2 284-286, IL-4 287, IFN-γ 288 and CTLA-4 289. 
The MAPK-inhibitor (PD98059) only partially inhibited activation-induced FOXP3 
mRNA expression, suggesting that the AP-1 factors can be mobilized by others 
pathways. In contrast, CsA completely inhibited the mRNA induction of FOXP3 as 
well as the promoter activity. CsA is a well-known immunosuppressive drug which, 
blocks NFAT translocation into the nucleus by inhibition calcineurin phosphatase 
activity 290. We have previously shown that immunosuppressant glucocorticoids 
promote FOXP3 expression 262, whereas rapamycin does neither enhances nor 
decreases FOXP3 (data not shown and 291,292). Therefore immunosuppressive drugs 
may have different mechanisms to promote tolerance induction. 
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Alternatively, immunosuppressive drugs may also act on pre-existing Tregs that are 
only marginally affected by TCR engagement in terms of FOXP3 mRNA expression, 
which is already high in resting Tregs. This marginal enhancement of FOXP3 
expression in already existing, anergic Tregs is resistant to CsA expression, 
confirming previous studies, showing that anergic cells are impaired in Ca++/NFAT 
mobilization 293,294. However, pre-activation shows a dramatic increase on the 
suppressive capacity of the CD4+CD25+ Treg cells. Pretreatment of the CD4+CD25+ 
cells with CsA had just a minor effect on the suppressive capacity and suggest that 
NFAT is not essential in the process of suppression. In fact, CD4+CD25+ Tregs have 
been shown to be anergic and hyporesponsive to TCR stimulation and unable to 
induce Ca++ signaling, that may explain that those cells are unable to further induce 
FOXP3 expression upon activation 295.  
Taken together our results indicate that the FOXP3 promoter is cell-specific and is 
active only in primary T cells. The identified basal promoter has similarities to 
immunological genes carrying elements including NFAT and AP-1, which are 
induced following TCR engagement. The reporter-constructs provide new tools to 
identify mechanisms underlying tolerance induction and potential therapeutic 
interventions.  
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Table  I. Primer. Primers FoxP3 rev, 1657, -1210, -511, -307 and -211 introduced a 
restriction enzyme recognition site for KpnI or XhoI. The primers used for mutational 
analysis are also shown. The underlined letters denote mutated nucleotides. 
 
Name Sequence (5’ → 3’) Purpose a 
FOXP3 +176 rwd AACTCGAGACCTTACCTGGCTGGAATCACG Cloning 
Fox-1657  AAGGTACCCTTGGCCACCAGATTTGTACC Cloning 
Fox-1210 AAGGTACCCTACCTCCGTTTCCCTCATCTG Cloning 
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Fox –511 AAGGTACCTTCCCATCCACACATAGAGC Cloning 
Fox-307 AAGGTACCATACCTCTCACCTCTGTGGTG Cloning 
Fox –211 AAGGTACCAGTCTCATAATCAAGAAAAGG Cloning 
TATA –34 GCGTGGTTTTTCTTCTCGGTCTCGAAGCAAAGTTGTTTTTGATACG Mutation 
GC Sp1 - 142 
NFAT -328  
NFAT -490 
AP-1 -476 
NFAT –383 
anchor primer 
RACEFOXP3+987 
RACEFOXP3+521 
GAGAGAAAAAAAAAACTATGAGAACCTTTTCCCACCCCGTGATTATCAGCGC 
CTATACACTTTTGTTTTAAAAACTGTGGGAGCTCATGAGCCCTATTATCTCATTGATACC 
CATAGAGCTTCAGATTCTCTTTCTTGGACCAGAGACCCTCAAATATCCTCTCAC 
TCATGAGCCCTATTATCTCCACGATACCTCTCACCTCTGTGG 
GTTGGCCCTGTGATTTATTTTAGTTCTCGAGCCTTGTTTTTTTTTTTTCAAACTCTATACAC 
GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG 
CACCCGCACAAAGCACTTG 
GCTGCTCCAGAGACTGTACCATCT 
Mutation 
Mutation 
Mutation 
Mutation 
Mutation 
RACE 
RACE 
RACE 
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Summary 
 
The origin of regulatory T cells (Tregs), controlling inflammatory responses against 
autoantigens or allergens is unknown. The present study describes a mechanism 
repressing peripheral Treg induction on the basis of the FOXP3 promoter analysis and 
challenges the idea of a shared developmental pathway with T helper type I (Th1) or 
Th2 lineages. Instead present data favor the concept of a distinct lineage whereby 
Tregs develop alternatively to Th1 or Th2 cells. We demonstrate that cytokines such 
as IL-4 and TGF-β present at the time of T cell priming of the uncommitted cells are 
decisive not only in differentiating T cells towards effector phenotypes, but also 
towards Tregs. Moreover, Th2-driving conditions that occur in allergic inflammation 
prevent the induction of Tregs by a GATA3-mediated inhibition of the FOXP3 
promoter. Since IL-4 treatment in mice reduces Treg frequency, therapeutic 
approaches targeting IL4 and/or GATA3 might provide new preventive strategies 
facilitating tolerance induction. 
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 Introduction 
 
Effective immune responses are characterized by T cell activation, which directs 
adaptive and innate immune responses to efficiently kill pathogens. Dependent on the 
pathogen, T cells differentiate into different subtypes such as Th1 or Th2 cells, which 
are most efficient in defeating microbial or parasitic invaders respectively. The 
balance between Th1 and Th2 cells has been the starting point for therapeutic 
interventions 296. A hallmark of Th1 and Th2 differentiation pathways is the 
exclusiveness of the individual mechanisms. IL-12 mediated STAT4-phosphorylation 
102 and T-bet expression are essential for Th1 differentiation 297,298. In contrast, IL-4-
induced STAT6 and GATA3 inhibit differentiation into Th1 cells in the early phase of 
commitment 85,101. GATA3 is sufficient to induce Th2 phenotypes 299 and acts not 
only through induction of IL-4, IL-5 and IL-13, the Th2 cytokines, but also through 
inhibition of Th1 cell-specific factors 299. Recently it could be shown that T-bet 
directly modulates GATA3 function 300, suggesting that transcription factors compete 
in the early differentiation phase of T cells to finally imprint the T cell phenotype 301. 
A GATA3 dominated immune response has been shown to be essential for airway 
hyperresonsiveness 302 and can break antigen-specific immune tolerance 303. 
Overexpression of a dominant negative form of GATA3 304 or treatment with 
antisense-mediated GATA3 blockade 305 decreased the severity of the allergic airway 
hyperresponsiveness. 
The discovery of Tregs highlights another phenotype of T cells, which is essential for 
tolerance against autoantigens. However its integration in lineage development is not 
fully clear. Naturally-occurring Tregs (nTregs) are generated in the thymus and are 
assumed to protect against the activity of autoreactive T cells in the periphery. These 
cells express the forkhead transcription factor FOXP3 and constitutively express 
CD25 on their surface, but lack cytokine expression, which would set them in 
proximity of Th1 or Th2 lineages. Particularly interesting are Tregs, which are 
generated in the periphery and thus are potential targets for therapeutic intervention. 
These induced Tregs (iTregs) were reported to express FOXP3, however expression 
may be transient 306. The exact circumstances of iTreg generation are unclear, but 
TGF-β has been demonstrated to be important for the induction of these cells in vitro 
and in vivo, since animals lacking the TGF-βRII on T cells are deficient in 
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peripherally-iTregs and suffer from a T cell dependent multiorgan inflammatory 
disease 64,191,210,307,233. Although the effect of TGF-β on Treg induction is well 
documented, its molecular targets remain to be identified. 
Two different scenarios of Treg induction can be hypothesized: one, in which Tregs 
can be induced in already committed effector cells, which provides a scenario of an 
inherent shutdown mechanism of T cell activation. The other suggests that Tregs 
differentiate from naïve T cells as a separate lineage in a similar fashion as known for 
Th1 or Th2 commitment, a scenario providing a suppressive memory population. The 
current study provides evidence for the second model and focusses on GATA3 and 
FOXP3 which may play a similar role in Treg commitment as T-bet and GATA3 for 
Th1 and Th2 differentiation respectively. This assumption is based on the observation 
that TCR activation is necessary to generate Tregs as well as the FOXP3 gene and 
that high and stable FOXP3 expression is sufficient to generate a regulatory 
phenotype 240-242. We show that GATA3 excludes FOXP3 expression and that IL-4, 
and thus Th2 cells inhibits FOXP3 expression both in vitro and in vivo. We 
demonstrated that GATA3 directly binds to the FOXP3 promoter and thereby inhibits 
the induction of this gene, supporting a concept of a separate cell lineage for Treg 
commitment. 
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Results 
 
Exclusive commitment of Tregs  
To investigate whether FOXP3 can be expressed by any T cell subset or is restricted 
to a distinct lineage, FOXP3 mRNA expression was analyzed in freshly isolated T 
cell such as CD25-depleted CD4+cells, CD45RA+ naïve or CD45RO+ memory T cells 
as well as T cells driven in vitro towards Th1, Th2 or iTreg cells (Figure 14A). The 
CD4+CD25-, CD45RA+, CD45RO+ and CD4+CD45RO+CD25- were able to 
significantly induce FOXP3 mRNA up to 40 - 50-fold upon TCR activation and 
addition of TGF-β. Th1 cells showed only a 10-fold increase. In contrast, Th2 cells 
stimulated under the same conditions did not increase FOXP3 expression. The in vitro 
iTregs were unable to further upregulate FOXP3, which was already high under the 
resting conditions (Figure 14A). 
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Figure 14. Th2 cells cannot induce FOXP3 expression 
(A) Human T cells were activated with plate-bound anti-CD3/CD28 with or without TGF-β. 
Cells were harvested after 5 days and FOXP3 mRNA was quantified by real-time PCR. Bars 
show the mean ± SD of 4 independent experiments.  
(B) Th2 cells were activated with anti-CD3/CD28, TGF-β or anti-IL-4 as indicated. Bars 
show the mean ± SD of 3 independent experiments.  
(C) FACS analysis of intracellular FOXP3 expression of Th1, Th2 or i Treg differentiated (2 
rounds) cells in activated or resting conditions in the presence of TGF-b. FOXP3 expression 
was measured after five days in culture. The dot blots are representative of three independent 
experiments. 
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Th2 cells are known to produce IL-4 upon activation, which may interact with TGF-β 
signaling and thus prevent FOXP3 induction. However, the neutralization of IL-4 
with a blocking IL-4 antibody, did not rescue FOXP3 expression in the differentiated 
Th2 cells. These data demonstrated that Th2 have a limited capacity to express 
FOXP3 (Figure 14B). 
The inability of Th2 cells to express FOXP3 was also documented at the single cell 
level, revealing that Th2 cells lack FOXP3 expression under any condition, 
confirming the mRNA analysis (Figure 14C). Only iTregs expressed FOXP3 in 
resting conditions. Interestingly, we observed that resting iTregs express FOXP3, but 
show low CD25 surface expression. Repeated exposure to TGF-β did not further 
increase the FOXP3 expression in the iTreg lineage, but induced transiently FOXP3 
expression in Th1 cells.  
Taken together these results indicate that FOXP3 can be induced in naïve T cells, but 
not in commited Th2 cells, which may lack factors necessary for FOXP3 expression 
or have an inhibitory mechanism that affect their ability to express FOXP3. 
 
FOXP3 and GATA3 kinetic in differentiating cells 
The limited capacity of differentiated effector cells to induce FOXP3 expression, 
suggested that Treg induction has to occur before differentiation. Following initiation 
of the differentiation process FOXP3 and GATA3 show a similar activation kinetic 
within the first three days, which are considered to be critical in commitment 275. 
Under Th2 differentiation conditions FOXP3 expression increased marginally during 
the first hours and then decreased to background levels (Figure 15A). The Th0 and 
Th1 cells expressed a higher level than the Th2, but lower than the iTregs (data not 
shown). Thus, although GATA3 and FOXP3 show similar kinetics, their expression is 
mutually exclusive. 
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Figure 15: FOXP3 induction during the differentiation process. 
(A) CD4+CD45RA were activated with plate-bound anti-CD3/CD28 in the presence of TGF-
β (5 ng/ml)or IL-4 (25 ng/ml). The cells were harvested at different time-points and mRNA 
was quantified by real-time PCR for FOXP3 and GATA3 expression. Bars show the mean ± 
SD of 3 independent experiments.  
(B) and (C) in vitro differentiated Th1, Th2 or iTregs were restimulated with plate-bound 
anti-CD3/CD28. Cells were harvested after 3 days for real-time PCR (B) or western blot 
analysis (C) of FOXP3, GATA3 and T-bet; GAPDH served as internal control. Data are 
representative of three independent experiments. 
 
The selective expression of FOXP3 was even more apparent three days after 
restimulation of the cell lineages, where FOXP3 mRNA and protein were exclusively 
detected in Tregs (Figure 15B and C). These cells displayed phenotype comparable to 
nTregs, including an anergic phenotype upon anti-CD3 re-stimulation, CD103, 
CTLA-4, GITR and PD-1 surface expression (Figure 16A and B). The iTregs neither 
produced the Th1 cytokines IFN-γ nor the Th2 cytokines IL-4 or IL-13, upon 
activation with PMA and ionomycin, as determined by FACS (Figure 17) and ELISA 
(data not shown). 
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Figure 16: iTregs have a different phenotype than the Th1 and Th2. 
(A) in vitro differentiated Th1, Th2 or iTregs were stimulated as indicated and proliferation 
was measured after 3 days by thymidine incorporation overnight. Bars show the mean ± SD 
of 3 independent experiments.  
(B) Surface markers were measured by flow cytometry. The data are representative of three 
independent experiments. 
 
 
These data demonstrated that FOXP3 and thus Tregs are in fact co-evolving with Th1 
and Th2 cells as a separate lineage. 
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Figure 17: IL-4, IFN-γ and IL-13 cytokine production by Th1, Th2 and iTregs. 
Differentiated T cells were stimulated with PMA and ionomycin during 4 hours and subjected 
to intracellular staining by FACS. The data are representative of three independent 
experiments.  
 
IL-4 inhibits TGF-β-mediated Treg commitment 
To characterize the molecular nature of Treg  commitment, we investigated GATA3 
and FOXP3 expression in the presence of IL-4 and TGF-β in the early differentiation 
phase of T cells into Th2 and Treg conditions. Human CD4+CD45RA+ T cells were 
activated with plate-bound anti-CD3/CD28 in the presence of TGF-β and/or IL-4 and 
harvested after 5 days. IL-4 efficiently repressed the TGF-β-mediated induction of 
FOXP3 expression (Figure 18A) in a dose-dependent manner (Figure 18B). Of note, 
GATA3 was also induced in the presence of TGF-β at high IL-4-concentration 
(Figure 18A and B). These IL-4-treated cells (Figure 18A) were not able to suppress 
proliferation of autologous target T cells in an in vitro suppression assay (data not 
shown). The IL-4-mediated prevention of FOXP3 expression was not caused by 
interferences of the receptor signalling, since the phosphorylation of SMAD2 or 
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STAT6 was not affected by the addition of IL-4 and/or TGF-β, demonstrating that IL-
4 as well as TGF-β signalling were functional under these conditions (Figure 18C). 
Furthermore IL-4 was inhibiting TGF-β-mediated generation of FOXP3+ T cells, as 
shown by FACS analysis (Figure 18D). 
 
 
 
Figure 18: IL-4 inhibits TGF-β  mediated Treg commitment. 
(A) CD4+CD45RA+ were activated with plate-bound anti-CD3/CD28 during five days in 
presence of TGF-β (10 ng/ml) and with or without IL-4 (100 ng/ml). The cells were harvested 
and mRNA was quantified by real-time PCR for FOXP3 and GATA3 expression. Bars show 
the mean ± SD of 6 independent experiments. Statistical analysis was performed using the 
Dunnett test. Statistical significance is indicated by asterisks (* = p≤ 0.05, ** = p≤ 0.01). 
(B) CD4+CD45RA+ cells were activated in the presence of a constant concentration of TGF-β 
(5 ng/ml) with an increasing concentration of IL-4, as indicated. Cells were harvested after 
five days for mRNA quantitation.  
(C) CD4+CD45RA+ cells were stimulated in vitro with plate-bound anti-CD3/CD28, TGF-β 
(10ng/ml) and IL-4 (100 ng/ml) as indicated. After 1 h, cell lysates were prepared and 
analyzed by western blot for phosphorylated SMAD2 and STAT6. Total STAT6 and GAPDH 
served as internal control.  
(D) CFSE-labeled CD4+CD45RA+ were activated with plate-bound anti-CD3/CD28, TGF-β 
and IL-4, as indicated. After 5 days, cells were analyzed by flow cytometry. CFSE profiles, 
surface CD25 and intracellular FOXP3 expression are shown on the left panels. On the right 
comparison of CFSE profiles for FOXP3+ and FOXP3- cells is shown for the conditions as 
described. Data are reprentative of four independent experiments. 
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It is known that IL-4 is a potent growth factor and may therefore favor the 
proliferation of (FOXP3-) effector cells and thus decrease the relative percentage of 
FOXP3+ cells. However, analysis of cell division kinetics by CSFE labelling 
demonstrated that IL-4 did not differentially promote cell growth of FOXP3+ and 
FOXP3-. In fact both populations showed similarly enhanced proliferation and more 
cells were able to reach three cycles of division (Figure 18D, right panel). 
Furthermore the TGF-β-mediated induction of FOXP3 expression was not caused by 
overgrowth of a CD25-FOXP3+ minority, since the number of FOXP3+ cells was 
low/absent in the purified CD4+CD45RA+ T cells (between 0 and 1 %) and the 
FOXP3+ cells were not confined to the highly divided cells. The FOXP3+ T cells were 
generated from FOXP3- T cells, since level of non-dividing FOXP3+ cells increased, 
revealing FOXP3+ induction out of FOXP3- cells (Figure 18D, left panel). CD25 was 
downregulated in TGF-β-treated cells compared to activated T cells, which was even 
more pronounced in cells cultured with TGF-β and IL-4. The FOXP3+ T cells are 
shown to be CD25+ at this early stage of differentiation (Figure 18D left panel). 
These results show that IL-4 acts in vitro as an inhibitor of FOXP3 expression, 
without interfering with TGF-β signaling, probably acting at the level of transcription 
factors. 
 
GATA3 is a negative regulator of FOXP3 expression 
The data presented above showed that IL-4 potently represses Treg commitment 
without affecting TGF-β signaling. GATA3 was previously shown to repress Th1 
commitment by inhibiting STAT4 expression 101,102 and therefore to prevent 
differentiation into Th1 cells. Thus we hypothetized a potential role for GATA3 in 
repressing FOXP3 and therefore preventing the commitment to Tregs. To see whether 
GATA3 can directly inhibit FOXP3 induction, we overexpressed GATA3 in human 
primary CD4+CD45RA+ T cell. After transfection, the cells were activated with 
soluble anti-CD3/CD28 in the presence or absence of TGF-β. GATA3-transfected 
cells showed a lower FOXP3 mRNA level when treated with TGF-β compared to the 
cells transfected with the control vector (Figure 19A, left panel). Successful GATA3 
expression was controlled by western blot analysis (Figure 19A, right panel). This 
result revealed that GATA3 directly inhibits the Foxp3 gene. Since transient 
overexpression may be limited by time and transfection efficiency, we analyzed the 
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inhibitory effect of GATA3 on FOXP3 in transgenic DO11.10 mice, overexpressing 
GATA3 under the control of the human CD2 locus control region (DO11.10xCD2-
GATA3). This model provides OVA-specific CD4+ T cells expresssing GATA3 
constitutively. The frequency of peripheral natural occuring T regs 
(CD4+CD25+Foxp3+) in these mice was slightly decreased compared to DO11.10 
littermate control mice (Figure 20). Furthermore thymic selection into the CD4 
lineage is largely intact in DO11.10 x CD2-GATA3 (R.W.Hendriks, unpublished 
data). These mice develop thymic lymphomas at older age, but signs of autoimmune 
disease were not described 308. To investigate the effect of GATA3 on iTregs, 
CD4+CD62L+CD25- cells were isolated, activated with OVA in the presence or 
absence of TGF-β and Foxp3 expression was analyzed after four days. The naïve 
CD4+CD25- cells were Foxp3- (data not shown) and activation with the OVA antigen 
did only marginally induce Foxp3+ cells. As described for the human cells, TGF-β 
dramatically upregulated Foxp3 in the DO11.10 littermate control mice. In contrast, 
cells from the CD2-GATA3xDO11.10 mice were almost unable to upregulate Foxp3, 
when activated with TGF-β and OVA (Figure 4B). All mice produced similar 
amounts of TGF-β and Smad7 was equally expressed 309 in T cells of both mice 
strains (Figure 19C), indicating intact TGF-β signaling. Taken together these results 
demonstrated a repressive role of IL-4-induced GATA3 transcription factor in the 
generation of iTregs. 
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Figure 19: GATA3 acts as a negative regulator of FOXP3 expression. 
(A) human CD4+CD25-  cells were transfected with a GATA3 or GFP (as negative control) 
expression construct and treated with anti-CD3/CD28, and TGF-β, as indicated. The mRNA 
was analyzed after 3 days by real-time PCR.  
(B) CD4+CD25- cells were isolated from D011.10 and D011.10xCD2-GATA3 mice and 
treated with OVA and TGF-β for 96 h. Surface CD4 and intracellular Foxp3 were measured 
by FACS. These data are representative of 3 different experiments.  
(C) The cells treated as in (B) were harvested and mRNA was quantified by real-time PCR 
for SMAD7 and TGF-β expression. Bars show the mean ± SD of 3 independent experiments.  
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Figure 20: CD2-GATA3xDO11.10 CD4+Tcells do have Foxp3+ T cells. 
(A) CD4+ T cells from CD2-GATA3xDO11.10 or DO11.10 WT mice were isolated from 
pooled lymph nodes and spleens and analyzed by FACS for CD25+ and CD4+ cells 
(B) CD4+CD25- and CD4+CD25+ from CD2-GATA3xDO11.10 or DO11.10 WT were 
analyzed for Foxp3 expression. The CD2-GATA3xD011.10 show a reduced number of 
FOXP3+ cells in the CD4+CD25+ population. The data are representative of three independent 
experiments. 
 
GATA3 directly binds to and represses the FOXP3 promoter 
To investigate the molecular mechanism of GATA3 mediated repression of FOXP3, 
the human FOXP3 promoter was studied and a palindromic binding site for GATA3 
was discovered. The GATA-binding site is located -400 bp upstream from the 
transcription start site, in a region which has already been described as important for 
the regulation of FOXP3 expression 310. This site is highly conserved between human, 
mice and rat (Figure 21) and may therefore play an important role in FOXP3 
regulation. The functional relevance of this site was studied using an established 
FOXP3-promoter construct 310. We transfected human primary CD4+ T cells and 
Jurkat cells, the latter constitutively expressing GATA3 311,312 and measured FOXP3 
promoter activity. The promoter was not active in the GATA3-expressing cell line 
Jurkat, whereas the construct was active in the CD4 cells, which express a lower 
amount of GATA3 (Figure 22A). A site-specific mutation abolishing the GATA3-
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binding site of the human FOXP3 promoter increased luciferase activity by 2.5-fold in 
CD4+ T cells, revealing a repressor activity of GATA3 on the FOXP3 promoter 
(Figure 22B). Overexpression of GATA3 diminished luciferase activity of the FOXP3 
promoter compared to the control vector (pcDNA3; Figure 22C).  
 
 
Figure 21: Localisation of the human FOXP3 promoter in a highly conserved region of 
the FOXP3 gene.  
Structure of the FOXP3 gene and sequence conservation of the human (top: GenBank 
accession number AF235097), mouse (middle: accession number AF277994) and rat (bottom: 
GenBank accession number NW_048035) are shown. The transcription start site (TSS) is 
indicated by an arrow. GATA3-binding sites are indicated by a box.  
 
 
The ability of GATA3 to physically interact with the FOXP3 promoter was further 
investigated. Cells which normally do not express GATA3 (HEK) were transiently 
transfected with GATA3- or control-genes and increasing amounts of lysates were 
incubated with oligonucleotides containing the GATA3-site of the FOXP3 promoter 
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or a control oligonucleotide with a mutated GATA3 binding site. These 
oligonucleotides were precipitated and GATA3-specifically detected by western blot. 
Similarily, GATA3-expressing Th2 cells and iTregs were subjected to this approach. 
Only HEK cells overexpressing GATA3 (Figure 22D) and Th2 cells (Figure 22E) 
showed GATA3-binding activity. This experiment proves that GATA3 can bind the 
FOXP3 promoter, but leaves open, whether this binding activity also occurs in an 
intact T cell. Therefore we performed a chromatin coimmunoprecipitation (ChIP) 
using a GATA3-specific antibody to precipitate chromatin of Th2 cells and iTregs. In 
line with the previous experiments,  we could detect GATA3 binding to the FOXP3 
promoter in Th2 cells, but not in the iTregs (Figure 22F). 
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Figure 22: GATA3 binds to and represses the human FOXP3 promoter. 
(A) Jurkat and human primary CD4 cells were transfected with an empty vector (pGL3 basic) 
or vector containing the putative FOXP3 promoter region. Bars show the mean ± SD of 
arbitrary light units normalized for renilla luciferase of 4 independent experiments; samples 
were measured as triplicates.  
(B) CD4 cells were transfected with wild-type or a GATA3 mutated FOXP3 promoter 
reporter construct. Bars show the mean ± SD of 3 independent experiments.  
(C) Overexpression of GATA3 in CD4 cells with the 511 FOXP3 promoter construct 
decreases the luciferase activity of  the FOXP3 promoter. Results shown are the mean ± S.D. 
of 3 different experiments performed in triplicate.  
(D) Nuclear extracts were prepared from HEK cells transfected with GATA3 or an empty 
vector. Biotinylated oligonucleotides were absorbed by streptavidin agarose beads and then 
incubated with nuclear extracts. The amounts of GATA3 protein in the precipitates were 
assessed by immunoblotting with anti-GATA3 mAb. Total nuclear extracts were also run as 
controls. These data are representative of 3 different experiments. 
(E) Nuclear extracts from Th1, Th2 and iTregs were collected and tested for GATA3 binding 
activity as in (D). This experiment is representative of 3 experiments. (F) Th2 and iTregs 
were analyzed by ChIP for GATA3 binding to the FOXP3 promoter. Shown is the PCR for 
the FOXP3 gene after reversing the cross-linking. The “input” represents PCR amplification 
of the total sample, which was not subjected to any precipitation. Results are representative of 
three independent experiments. 
 
 
Taken together these data demonstrated that GATA3 directly binds the FOXP3 
promoter and inhibits its activity. 
 
IL-4 does not affect FOXP3 expression of existing, terminally differentiated Tregs. 
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The dramatic effects of GATA3 in preventing Treg commitment may also alter the 
FOXP3 expression and suppressive function of already existing, terminally 
differentiated Tregs. Accordingly terminally-differentiated iTregs as well as natural 
CD4+CD25high Tregs were activated and treated with IL-4. In contrast to the potent 
effect of IL-4 on differentiating cells, IL-4 was not able to decrease FOXP3 mRNA 
expression in either the natural (Figure 23A) or on existing iTregs (Figure 23B).  
Furthermore pre-activation of natural Tregs with anti-CD3/CD28 and IL-4 did not 
diminish the suppressive capacity of these cells (Figure 23C). These results reveal that 
GATA3 inhibits Tregs primarily during the differentiation process.  
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Figure 23: IL-4 does not revert Treg phenotype in vitro. 
(A-G) CD4+CD25high cells were FACS-sorted and activated with plate-bound anti-CD3/CD28 
plus IL-2 during 3 days and in the presence or absence of IL-4 (100 ng/ml) and harvested for 
real-time PCR analysis. The results shown represent the mean ± S.D. of three independent 
experiments.  
(B) Tregs were induced in vitro and treated as described in (A).  
(C) Activation dramatically increases CD4+CD25+ Tregs suppressive capacity of 
CD4+CD25+ Tregs. CD4+CD25+ Tregs were preactivated during 2 days in the presence or 
absence of an increasing IL-4 concentration. After virgorous washing, their suppressive 
capacity on responder CD4+CD25- was tested. IL-4 pretreatment did not affect the suppressive 
capacity of FACS-sorted CD4+CD25high cells. 1x104 CD4+CD25+ Tregs were added to 5x104 
CD4+CD25- and 5x104 irradiated PBMCs. The results are representative of three independent 
experiments. 
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Effect of IL-4 on Tregs in vivo 
To verify the striking effect of IL-4 on Treg commitment in vivo, we injected IL-4 into 
normal wild-type B6 mice. We used complexes of recombinant mouse IL-4 (rmIL-4) 
plus anti-IL-4 monoclonal antibodies (mAb), which have been shown to dramatically 
increase the potency of the cytokine in vivo 313. Mice injected with rmIL-4 or anti-IL-
4 mAb alone did not show signicant changes in the frequency of CD4+CD25+ cells 
(Figure 24A-C, E). In contrast the percentage of CD4+CD25+ T cell dramatically 
decreased, when the cytokine antibody complexes were injected (Figure 24D, F). 
Preliminary data confirmed that the decrease of CD25+ T cells reflected a decrease in 
Foxp3+ T cells, as measured by Foxp3 intracellular staining. This effect was specific 
for IL-4 and not for the mAb, since another anti-IL-4 mAb also decreased the Treg  
frequency only in combination with IL-4 (Figure 24 E, F). Upon administration of 
rmIL-4 plus anti-IL-4 mAb complexes, the total number of CD4+CD25+ T cell 
diminished by half (Figure 24G), confirming that the lower percentage was not due to 
an increase in the CD4+CD25- cells, but a real decrease of CD4+CD25+ cells. In 
conclusion IL-4 negatively regulates the Treg turnover not only in vitro but also in 
vivo.  
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Figure 24: In vivo treatment of mice with IL4 antibody-cytokine complexes. 
(A-G) Normal B6 mice were given every other day ip injections of phosphate-buffered saline 
(PBS), recombinant mouse IL-4 (rmIL-4), anti-IL-4 monoclonal antibody (anti-IL-4 mAb, 
11B11 or MAB404), or a mixture of rmIL-4 plus anti-IL-4 mAb (11B11 or MAB404). Mice 
were analyzed on day 7 by flow cytometry for CD3, CD4 and CD25 expression.  
(A-F) Shown is CD25 versus CD4 expression in CD3+ CD4+ spleen cells. Numbers indicate 
percentages of CD4+ CD25high CD3+ cells.  
(G) Total cell counts of CD4+ CD25high cells in spleen from mice in (A-F) are shown as 
mean ± SD. The data are representative of three independent experiments. 
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Discussion 
 
The current study reveals that FOXP3-mediated Treg  commitment is inhibited by 
GATA3, which is the key regulator for polarization towards Th2 cells. After 
differentiation the effector cells become refractory to conversion into a regulatory 
phenotype and particularly Th2 cells were unable to upregulate FOXP3. In 
accordance with other studies, we found that CD4+CD25- were able to upregulate 
FOXP3 63,306. Already committed cells such as memory T cells and Th1 cells showed 
only moderate and transient FOXP3 induction. Particularily Th2 cells were lacking 
FOXP3 under all circumstances, which was not caused by endogenous production of 
IL-4, since IL-4 neutralization did not restore FOXP3 expression. Predominantly 
naïve T cells could efficiently upregulate FOXP3, suggesting, that FOXP3 plays an 
important role in the early differentiation process and may act in a similar way as it is 
known for GATA3 and T-bet, which are essential for commitment of naïve T cells 
towards Th2 and Th1 respectively. This commitment is characterized by competitive 
and exclusive expression of these factors 100,314, which we also observed during the 
differentiation of FOXP3+ iTregs, lacking GATA3 or T-bet expression. In this 
competitive process TGF-β appeared to be mandatory for the induction of FOXP3, 
possibly by keeping the expression of GATA3 and T-bet low 315,316. In contrast, 
differentiating naïve T cells under neutral, “Th0” conditions showed only a transient 
FOXP3 expression and failed to generate a stable population of FOXP3 expressing 
cells, but GATA3 and T-bet were upregulated (data not shown). Interestingly, as we 
and other previously described, FOXP3-inducing factors, such as dexamethasone 262, 
CTLA-4 317 and estrogens 263, are also known as inhibitor of GATA3 expression 318-
321. As a result of the differentiation process iTregs evolve as a separate lineage, 
characterized by its suppressive function and a distinct cytokine and surface receptor 
profile relative to Th1/Th2 cells.  
The successful polarization of naïve T cells towards a Th1 or Th2 immune response is 
balanced by cytokines. In this context we demonstrated that IL-4 was able to inhibit 
stable FOXP3 induction mediated by TGF-β and therefore prevented the conversion 
into the regulatory phenotype. IL-4 has already been shown to negatively regulate the 
development of naïve T cells into Th1 or the recently-described IL-17 produing T 
cells (Th17) T cells (Harrington et al., 2005; Pace et al., 2005). Similar effect has 
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been recently described for IL-6, which inhibits combined with TGF-β the generation 
of iTregs and induced the differentiation into the Th17 cells by an unknown 
mechanism 323,324. We hypothesized that the IL-4-dependent mechanism could be 
mediated by GATA3 and demonstrated that GATA3-inducing IL-4 concentrations 
were repressing TGF-β-mediated FOXP3 expression, while IL-4 as well as TGF-β 
signaling were intact. This result suggested a competitive mechanism between 
GATA3 and FOXP3 transcription factors in determing lineage commitment during 
the early phase of differentiation. Accordingly we investigated whether GATA3 
overexpression affected FOXP3 induction and found that GATA3 overexpressing 
naïve human T cells were characterized by a reduced capacity to express FOXP3. 
This inhibitory effect of GATA3 was further confirmed in transgenic mice, 
expressing GATA3 in T cells (DO11.10:CD2GATA3 transgenic mice). In line with 
the transient overexpression of GATA3 in human T cells, cells of these mice failed to 
induce FOXP3 expression upon exposure with antigen in the presence of TGF-β. 
Strikingly, the DO11.10 CD2GATA3 mice do have peripheral FOXP3+ cells, which 
however displayed a 10 -25% lower frequency compared to WT DO11.10 mice. Thus 
GATA3 restrains the development of certain Tregs subsets, presumably the inducible, 
peripheral population and not those of thymic origin. Thymic T cells are undergoing a 
different maturation process, which may explain the insensitivity of nTreg to GATA3 
overexpression 208. Preliminary results indicate that the repressor of GATA3 (ROG) 
may play an important role in nTregs, as it has been shown for differentiation into 
CD8 cells in the thymus 142,325,326. Interestingly mice lacking GATA3 develop 
spontaneously into Th1 cells, however it is currently not known, how iTregs develop in 
these animals (Zhu et al., 2004). 
The current study demonstrated that GATA3 represses FOXP3 expression directly by 
binding to the FOXP3 promoter region. The palindromic GATA-site is located 303 bp 
upstream of the transcription start site (TSS) in a highly conserved region, which we 
have previously identified as the FOXP3 promoter 310. Site-specific mutation of this 
site increased the activity of promoter constructs, thus revealing the repressive nature 
of this GATA element. This palindromic GATA element binds GATA3 protein as 
proven by pull-down experiments. Furthermore, it is shown by chromatin immune 
precipitation that GATA3 binds this element also in intact cells, indicating that this 
chromatin region is accessible for GATA3 binding. It is known that GATA3 can 
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induce transcription by chromatin remodelling 110, by directly transactivating 
promoters 100 or, as shown in the current study, acts as a repressor of gene expression 
102,328,329. 
The molecular interactions enabling GATA3 to inhibit FOXP3 are not identified yet, 
but the GATA-binding site is located adjacent to positive, inducing sites, composed of 
AP-1-NFATc2 sites 310 and GATA3 may compete with the binding of AP-1/NFAT to 
the promoter (unpublished observations). 
The direct inhibition of FOXP3 by this GATA3 dependent mechanism could also 
affect already existing Tregs, by the same mechanism. However, IL-4 was ineffective 
to block FOXP3 expression or suppression of already existing Tregs, although IL-4R 
is expressed and functional on Treg (Pace et al., 2005). This finding underlines our 
hypothesis that Tregs are commiting as a separate lineage characterized by an 
imprinted phenotype. Once committed the T cells loose their capacity to convert to 
another phenotype (Grogan et al., 2001; Szabo et al., 1997; Harrington et al., 2005). 
To prove the inhibitory effect of IL-4 on Treg commitment in vivo, we treated mice 
with IL-4 and anti-IL-4. Only the IL-4/IL-4 mAb complex resulted in a decrease of 
the amount of Treg (CD25+ and FOXP3+) cells seven days after treatment. This 
enhancing effect of the antibody on cytokine effect has previously been described for 
IL-2 and IL-4 313. This finding might also explain a study, where anti-IL-4 mAb 
treatment was interpreted in the sense of IL-4 neutralization instead of IL-4 
potentiation 331. 
 
In summary, we demonstrated that GATA3 acts as an inhibitor of FOXP3 expression 
in early T cell differentiation, by directly binding and repressing the FOXP3 
promoter. These data support the idea that Tregs evolve as a separate lineage apart 
from the Th1 and Th2. These findings will give new perspectives in promoting 
peripheral tolerance to control autoimmune diseases and allergies on one hand and 
break tolerance against tumors on the other hand.  
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 Experimental procedures 
 
Mice 
Normal C57BL/6 (B6) mice were purchased from the Jackson Laboratories. 
Transgenic DO11.10 mice, expressing a T cell receptor for OVA323-339 peptide in the 
context of H-2d, were backcrossed with mice expressing GATA3, driven by the 
human CD2 locus control region (CD2-GATA3) 308, resulting in DO11.10xCD2-
GATA3 mice. Mice used for experiments were backcrossed on a BALB.C 
background for a minimum of eight generations and used at an age of 8-12 weeks. 
Mice were housed under specific pathogen-free conditions and all animal studies were 
performed according to institutional and state guidelines.  
 
Administration of Cytokines and Antibodies In Vivo 
Age- and gender-matched normal B6 mice received every other day intraperitoneal 
(ip) injections of PBS, 1.5 µg rmIL-4, 50 µg anti-IL-4 mAb (11B11 or MAB404), or a 
mixture of 1.5 µg rmIL-4 plus 50 µg anti-IL-4 mAb (11B11 or MAB404) for 7 days. 
Thereafter, spleen and LN cells were analyzed by flow cytometry for CD3, CD4 and 
CD25 expression. The anti-mouse IL-4 mAb MAB404 was obtained from R&D 
Systems, the second anti-mouse IL-4 mAb 11B11 was purchased from eBioscience. 
 
Isolation of CD4+ T cells 
CD4+ T cells were isolated from blood of healthy volunteers using the anti-CD4 
magnetic beads (Dynal, Hamburg, Germany) as previously described 269. The purity 
of CD4+ T cells was initially tested by FACS and was ≥ 95%. 
 
RNA isolation and cDNA synthesis 
RNA was isolated using the RNeasy Mini Kit (Qiagen, Hamburg, Germany) 
according to the manufacturer’s protocol. Reverse transcription of human samples 
was performed with TaqMan® reverse transcription reagents (Applied Biosystems, 
Rotkreuz, Switzerland) with random hexamers according to the manufacturer’s 
protocol. For the murine experiments, 100 ng RNA was reverse transcribed using 
Superscript II (Invitrogen) and random hexmamers (Amersham Biosciences, 
Roosendaal, The Netherlands) for 50 min. at 42 °C.  
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Quantitative real-time PCR 
The PCR primers and probes detecting human FOXP3 were designed based on the 
sequences reported in GenBank with the Primer Express software version 1.2 
(Applied Biosystems) as follows: EF-1α forward primer and reverse primer as 
described 332, FOXP3 forward primer 5` GAA ACAG CAC ATT CCC AGA GTT C 
3`, FOXP3 reverse primer 5` ATG GCC CAG CGG ATG AG 3`, GATA3 forward 
primer 5` GCG GGC TCT ATC ACA AAA TGA 3`. The prepared cDNAs were 
amplified using SYBR®-PCR mastermix (Biorad) according to the recommendations 
of the manufacturer in an ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems).  
Quantitative PCR of murine samples was performed with Brilliant SYBR Green 
QPCR master mix (Stratagene, La Jolla, CA, USA) and following primers: Ubiquitin 
C, 5’- AGGTCAAACAGGAAGACAGACGTA-3’ and 5’-
TCACACCCAAGAACAAG CACA-3’; Smad-7, 5’-GAAACCGGGGGAACGAAT 
TAT-3’ and 5’- CGCGAGTC TTCTCCTCCCA-3’; TGF-ß1, 5’- TGACGTCACTG 
GAGTTGTACGG-3’ and 5’-GGTTCATGTCATGGATGGTGC-3’. Primer pairs 
were evaluated for integrity by analysis of the amplification plot, dissociation curves 
and efficiency of PCR amplification. PCR conditions were 10 min. at 95 °C, followed 
by 40 cycles of 15 s at 95 °C and 60 °C for 1 min. using an 7300 real-time PCR 
system (Applied Biosystems). PCR amplification of the housekeeping gene encoding 
ubiquitin C was performed during each run for each sample to allow normalization 
between samples. Relative quantification and calculation of the range of confidence 
was performed using the comparative ΔΔCT method. 
 
Inducible murine Treg culture 
Naïve CD4+ T cells (CD4+, CD62L+, CD25-) were isolated from pooled lymph nodes 
and spleens by FACS-sorting (FACS Aria, BD).  5x105 T cells were co-cultured with 
2.5x104 bone marrow-derived dendritic cells 333 and 0.01  µg/ml  
OVA323-339 peptide (Ansynth, Roosendaal, The Netherlands) in the presence or 
absence of 20 ng/µl rhTGF-ß1 (Peprotech, Rocky Hill, NJ, USA) in 48-well plates. 
After four days, cells were harvested and analyzed for intracellular FOXP3 expression 
by FACS or gene expression by real-time quantitative RT-PCR. 
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In vitro T cell differentiation 
T cells were stimulated with immobilized plate-bound anti-CD3 (1 µg/ml, Okt3, 
IgG1) and anti-CD28 (2 µg/ml) in Th1 conditions: 25 ng/ml IL-12, 5 µg/ml anti-IL-4 
(R&D systems, Abingdon, UK), in Th2 conditions: 25 ng/ml IL-4, 5 µg/ml anti-IFN-
γ, 5 µg/ml anti-IL-12 (R&D systems) or Tregs conditions: 10 ng/ml TGF-β, 5 µg/ml 
anti-IFN-γ, 5 µg/ml anti-IL-12, 5 µg/ml anti-IL-4. Proliferating cells were expanded 
in medium containing IL-2 (30 ng/ml). 
 
Western blotting 
For FOXP3 analysis on the protein level, 1x106 cells CD4+CD25- were lysed and 
loaded next to a protein-mass ladder (Magicmark, Invitrogen) on a NuPAGE 4-12% 
bis-tris gel (Invitrogen). The proteins were electroblotted onto a PVDF membrane 
(Amersham Life Science, Dübendorf, Switzerland). Unspecific binding was blocked 
with BSA and the membranes were subsequently incubated with an 1:200 dilution of 
goat anti-FOXP3 in blocking buffer (Abcam, Hamburg, Germany) overnight at 4°C. 
The blots were developed using an anti-goat HRP-labeled mAb (Amersham 
Biosciences) and visualized with a LAS 1000 camera (Fuji, Urdorf, Switzerland). 
Membranes were incubated in stripping buffer and re-blocked for 1 h. The 
membranes were re-probed using anti-GATA3 (HG3-31; Santa Cruz Biotechnology), 
anti-T-bet (4B10, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-GAPDH 
(6C5, Ambion Ltd, Huntington, United Kingdom), anti-phospho-SMAD2 (138D4), 
anti-phospho-STAT6 (5A4) and anti-STAT6 (Cell Signaling technology, Allschwil, 
Switzerland),  
 
Cytokine production asssay 
T cells were stimulated with 2x10-7 M PMA and 1 µg/ml of ionomycin (Sigma 
Chemicals, St-Louis, MO, USA) for 4 h. The following mAbs were used: anti-IL-4-
PE (8D4-8, BD), anti-IL-13-PE (JES10-5A2, BD Biosciences), anti-IFN-γ-FITC 
(B27, BD Biosciences). Matched isotype controls were used at the same protein 
concentration as the respective antibodies. Four-color FACS was performed using an 
EPICSTM XL-MCL (Beckman Coulter, Nyon, Switzerland) using the software 
ExpoTM 32 version for data acquisition and evaluation. 
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Flow cytometry 
For analysis of FOXP3 expression at the single-cell level, cells were first stained with 
the monoclonal antibody CD25 (Beckman & Coulter), after fixation and 
permeabilization, cells were incubated with PE-conjugated monoclonal antibody 
PCH101 (anti-human FOXP3; eBioscience) based on the manufacturer's 
recommendations and subjected to FACS (EPICS XL-MCL). For cell surface marker 
staining, cells were incubated for 20 min at 4 °C in staining buffer with the following 
antibodies anti–CD152-PE (CTLA-4; BD), or anti–PD-1 (eBiosciences), anti-GITR 
(R & D Systems, Ltd), anti-CD69 (Beckman & Coulter), anti-CD103 
(DakoCytomation, Zug, Switzerland), anti-CD62L (Beckman & Coulter), anti-HLA-
DR (Beckman & Coulter). The controls were FITC, PE, or ECD-conjugated mouse 
IgG1 or rat IgG2a. For staining of mouse cells the following mAbs from BD 
Biosciences were used following standard techniques as described above: anti-CD3, 
anti-CD4, anti-CD25. Anti-FcγRII/III antibody (2.4G2, ATCC, Manassas, VA) was 
included in all stainings to reduce non-specific antibody binding. To isolate naïve 
murine CD4 T cells from murine DO11.10 or DO11.10xCD2-GATA3 T cells, cells 
were stained with anti-CD25-FITC, anti-CD62L-PE and anti-CD4-APC prior to 
sorting. Dead cells were excluded with 4',6-Diamidino-2-phenylindole (DAPI). To 
analyze murine Foxp3 expression in inducible Treg cultures, cells were stained 
intracellularly with anti-Foxp3-PE according to manufacturer’s instruction, in 
conjunction with anti-CD4-APC and LIVE/DEAD fixable dead cell stain kit 
(Invitrogen) to discriminate live cells. All monoclonal antibodies for murine cell 
stainings were purchased from eBioscience or BD Biosciences. 
 
Cloning of the FOXP3 promoter, construction of mutant constructs 
The FOXP3 promoter amplicon was cloned into the pGL3 basic vector (Promega 
Biotech Inc., Madison, WI, USA) to generate the pGL3 FOXP3 –511/+176. Site-
directed mutagenesis in the FOXP3 promoter region, were introduced using the 
QuickChange kit (Stratagene), according to the manufacturer’s instructions. The 
following primer and its complementary strand were used: GTT TCT CAT GAG 
CCC TAT TAA GTC ATT CTT ACC TCT CAC CTC TGT GGT GA. 
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Transfections and reporter gene assays 
T cells were rested in serum-free AIM-V medium (Life Technologies, Basel, 
Switzerland) overnight. An amount of 3.5 µg of the FOXP3 promoter luciferase 
reporter vector and 0.5 µg phRL-TK was added to 3 x106 CD4+ T cells resuspended 
in 100 µL of NucleofectorTM solution (Amaxa Biosystems, Cologne, Germany) and 
electroporated using the U-15 program of the NucleofectorTM. After a 24-hour culture 
in serum-free conditions and stimuli as indicated in the figures, luciferase activity was 
measured, by the dual luciferase assay system (Promega Biotech Inc.) according to 
the manufacturer’s instructions. Data were normalized by the activity of renilla 
luciferase. Jurkat cells were transfected using lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol. 
 
Pull-down Assay 
CD4+ T cells were stimulated with PMA and ionomycin for 2 h at 37°C. The cells 
were pelleted, resuspended in buffer C (20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, 1 mM DTT, protease inhibitors (Sigma, Buchs, 
Switzerland) and 0.1% NP-40) and lysed on ice for 15 min. Insoluble material was 
removed by centrifugation. The supernatant was diluted 1:3 with buffer D (as buffer 
C, but without NaCl). The lysates were incubated with 10 µg of poly(dI-dC; Sigma) 
and 70 µl of streptavidin-agarose (Amersham Biosciences) carrying biotinylated 
oligonucleotides, for 3 h at 4 °C. The beads were washed twice with buffer C/D (1:3) 
and resuspended in DTT-containing loading buffer (NuPAGE; Invitrogen), heated to 
70°C for 10 min and the eluants loaded next to a protein-mass ladder (Magicmark, 
Invitrogen) on a NuPAGE 4-12% bis-tris gel (Invitrogen). The proteins were 
electroblotted onto a PVDF membrane (Amersham Biosciences) and detected using 
an anti-GATA3 mAb (Santa Cruz Biotechnology). The blots were developed as 
described above. Accumulated signals were analyzed using AIDA software (Raytest, 
Urdorf, Switzerland). 
 
Chromatin Immunoprecipitation 
ChIP analysis was performed according to the manufacturer’s protocol (Upstate 
Biotechnology, Inc.) with the following modifications. iTregs and Th2 cells were 
fixed with 1% formaldehyde for 10 min at room temperature. The chromatin was 
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sheared to 200–1000 bp of length by sonication with five pulses of 10 s at 30% power 
(Bandelin). The chromatin was pre-cleared for 2 h with normal mouse IgG beads and 
then incubated with anti-GATA3-agarose beads (HG3-31; Santa Cruz Biotechnology) 
for 2 h. Washing and elution buffers were used according to the protocol of Upstate 
Biotechnology. Crosslinks were reversed by incubation at 65 °C for 4 h in the 
presence of 0.2 M NaCl, and the DNA was purified by phenol/chloroform extraction. 
The amount of DNA was determined by conventional PCR. The PCR addressed for 
the FOXP3 promoter region -246 to -511 and was performed using the following 
primers: 5’-GTG CCC TTT ACG AGT CAT CTG-3’ and 5’-GTG CCC TTT ACG 
AGT CAT CTG-3’. The PCR products were visualized using an ethidium bromide 
gel. 
 
FACS-sorting of human CD4+CD25+ 
PBMC were isolated from buffy coat by density gradient centrifugation over 
Ficoll/Hypaque gradient. Cells were stained with PE-anti-CD25 and anti-PE magnetic 
beads (Miltenyi Biotec, Bergisch Gladbach, Germany) and CD25+ cells were enriched 
using the Midi-MACS system (Miltenyi Biotec). CD25-enriched or -depleted cell 
populations were stained with FITC-anti-CD4 and sorted into CD4+CD25– and 
CD4+CD25high on a FACStar Plus (BD Biosciences).  
 
Suppression assay  
Samples in triplicate, containing 5x104 irradiated PBMCs, 5x104 CD4+CD25- and 
1x104 of preactivated or resting CD4+CD25+T cells per well were incubated in 96 
round-bottom-plates, which were previously coated with 1µg/ml antiCD3 mab or a 
matched isotype control. Cells were cultured for 4 days, pulsed for the last 10 h with 1 
µCi [3H]-thymidine (Hartmann, Braunschweig, Germany) and harvested on glass 
fiber filters using an automated multisample harvester (LKB, Pharmacia-Wallac, 
Turku, Finland).  Filters were transferred in sample bags with liquid scintillation fluid 
and analyzed using a β-scintillation counter (Pharmacia-Wallac). Round-bottom 96-
well plates were coated with 1 µg/µl anti-CD3 for 1 h at 37 °C and subsequently 
washed with PBS.  
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3. Discussion 
This thesis revealed mechanisms of FOXP3 gene expression regulation and provides a 
model of the molecular events underlying Treg cell generation. In a first step the 
promoter of the human FOXP3 gene was analyzed and led to the identification of 
NFAT1 and AP1 as inducer of FOXP3 after TCR triggering while GATA3 was 
discovered to act as a repressor of FOXP3 during differentiation into Th2 cells and in 
committed Th2 cells.   
 
3.1. Identification and characterization of the human basal 
FOXP3 promoter  
The human promoter was localized by 5’-RACE, at -6221 bp upstream from  the 
translation start site (TSS). The sequence upstream of the UTR shows a high degree 
of conservation between human, mouse and rat; which indicates that it contains 
important regulatory elements. The promoter shows cell-specific activity. It was 
active only in CD4+CD25- T cells but not in HELA, HEK or CHO cells.  
This region contains a functional TATA box as shown by mutational analysis and 
EMSA. This TATA box, which is located at –44 bp from TSS, is found in many 
genes near the transcription start site. The TATA box plays an important role in 
assembling the transcription machinery at promoters 334. It is bound by the TATA-
binding-protein, which recruits the RNA polymerase II, therefore playing a decisive 
role in transcription, as it has been shown for other genes such as IL-2 and IL-4 79,274. 
A GC box was identified –141 upstream the transcription start site and was proven to 
be functional. GC box binding proteins are able to induce basal promoter activity. Sp1 
can activate gene expression, whereas Sp3 can repress or activate transcription 277,335-
337. The Sp3-mediated repression has been shown as a result of competition with Sp1 
for the binding site 338,339, however Sp3 can also be a strong transcriptional activator. 
In case of the FOXP3 promoter it appears that Sp1 and Sp3 are not the only proteins 
to bind to the GC box, since the complex did not fully shift upon treatment with the 
antibodies against Sp1 and Sp3. Several factors have been identified to bind GC-rich 
region 273 like Sp4, BTEB1 (basic transcription element binding protein 1) 340, TIEG1 
and TIEG2 (TGF-β-inducible early protein genes 1 and 2) 341-343. Krüppel-like factors 
do not only bind GC boxes, but also structurally similar CACC-boxes, of which a 
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potential binding site is located near the GC box and may therefore have overlapping 
binding capacity to Sp1 and Sp3. Sp1 has been shown to regulate ubiquitously 
expressed housekeeping genes as well as cell type-specific and differentiation-specific 
gene 344,345. The promoter region -307/+176 was also weakly active in other cell lines, 
underlying the importance of other regulatory mechanisms like presence of cell-
specific enhancer or silencer. Gene expression might be regulated at the chromatin 
level as for many genes during differentiation of T cells, such as IL-4 and IFN-γ, in 
which chromatin opening is an important step in derepressing silenced genes 79,274 . In 
fact, we found that the chromatin was in a closed and restrictive conformation in non-
hematopoietic cells. In CD4+CD25- the chromatin was open, but after activation it 
was demonstrated to become more accessible as measured by histone acetylation.   
Therefore the human FOXP3 core promoter has a classical structure common to many 
genes. With a TATA box near the transcription start site at –44 bp and a GC box at –
141. These elements are characteristic of housekeeping genes and do not explain the 
cell-specific expression of FOXP3.  
 
3.2. Cell-specific activity of the FOXP3 promoter 
TCR stimulation of human CD4+CD25- T cells by an antigen can upregualte FOXP3 
expression in previously FOXP3- cells. Interestingly a region of the human FOXP3 
promoter seems to be particularly important in maintaining the activity of the 
promoter and is responsive to TCR stimulation. TCR-induction of the FOXP3 
promoter activity was mediated in an AP-1-NFATc2-dependent fashion and was 
blocked by the addition of the calcineurin inhibitor CsA. The activity of the NFAT 
proteins is tightly regulated by the calcium/calmodulin-dependent phosphatase 
calcineurin, which is inhibited by CsA 346. Calcineurin directly mediates the activation 
of NFAT molecule by dephosphrylation allowing migration into the nucleus 284. AP-1 
is composed of a heterodimer including Jun and Fos, and is activated through the 
MAPK kinase pathway 347. The inhibitors of MAPK kinase pathways only modestly 
repress the promoter induction as well as mRNA expression in activated CD4+CD25- 
T cells. Interestingly NFAT – AP-1 elements are found in many genes that are 
inducibly transcribed by TCR-triggering and is part of a common process of T cell 
activation 284,348-350. Site-specific mutations deleting these sites were decreasing 
activity of the promoter. The TCR-mediated induction of FOXP3 promoter activity 
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revealed and confirmed the importance of antigen experience in the thymus and in the 
periphery for Treg induction. 
3.3. Effects of immunosuppressive drugs on FOXP3 
expression 
The importance of TCR-triggering for generation and activation of Tregs suggests 
that immunosuppressive drugs might have different effect on the development of 
tolerance mediated by Tregs. Accordingly CsA inhibited potently the induction of 
FOXP3 in contrast to rapamycin. CsA is used in the treatment of atopic dermatitis and 
transplantation and has revolutionized transplant surgery since its introduction in 
1983 with a dramatic increase in the survival rate after transplantation 351. Rapamycin, 
a macrolide antibiotic produced by Streptomyces hygroscopicus, is a new effective 
drug used to prevent allograft rejection 352. However, unlike FK506 and CsA, 
rapamycin does not inhibit TCR-induced calcineurin activity. Rapamycin exerts its 
effect by binding to the intracellular immunophilin FK506-binding protein (FKBP12). 
The rapamycin-FKBP12 complex inhibits the serine/threonine protein kinase called 
mammalian target of rapamycin (mTOR), whose activation is required for protein 
synthesis and cell-cycle progression. Therefore, rapamycin blocks signaling in 
response to cytokines or growth factors, whereas FK506 and CsA exert their 
inhibitory effects by blocking TCR-induced activation 353. Consistent with this 
mechanism of action, it has been shown that rapamycin blocks T-cell-cycle 
progression from G1 to S phase after activation 353. Rapamycin promotes TCR-
induced anergy even in the presence of costimulation (Figure 25)354,355. 
Interestingly, it has been shown that rapamycin induces proliferation of CD4+CD25+ 
T cells, whereas CsA had an inhibitory effect 292. Therefore it can be concluded that 
CsA induce tolerance by directly inhibiting activation of effector cells, but at the same 
time it inhibits the generation of Tregs. The therapeutic usage of CsA may not 
promote the development of long-term cellular tolerance. Since every T cell has the 
potential to be activated by TCR, mechanisms that inhibit FOXP3 expression and 
therefore Treg commitment must exist. TCR triggering is probably only the first step 
in Treg commitment. 
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Figure 25: Rapamycin and CsA induce immune suppression by two different pathways. 
CsA targets calcineurin and NFAT –induction of gene transcription. However, rapamycin 
inhibits cell cycle progression and protein synthesis. CsA interferes with Treg turnover but 
not rapamycin. 
 
3.4. Models of Treg response to antigen 
Two models, which discriminate between recruitment and generation of Tregs on the 
site of antigen-triggered immune response, can be proposed to explain the role of 
FOXP3+ T cells in regulating the immune response. In the first model FOXP3+ T cells 
are recruited to the site of inflammation and will upon encounter with the antigens 
regulate the effector antigen-specific T cells and expand to control the intensity of the 
immune response. In the second model, FOXP3- cells are recruited and activated by 
the antigen and give rise to a clonal expansion of a mixture of two populations 
composed of effectors  and FOXP3+ Tregs. In the last model two different options can 
be hypothetized: already committed effector T cells upon activation can convert to 
Tregs while keeping their Th1 or Th2 profile. Alternatively,  Tregs only differentiate 
out of naïve T cells as a different lineage (Figure 26).  
In order to clarify this point, we analyzed FOXP3 inducibility in different subsets of 
cells. In accordance with other studies, we found that CD4+CD25- were able to 
upregulate FOXP3 63,306. Already committed cells such as memory T cells and Th1 
cells showed only moderate and transient FOXP3 induction. Interestingly Th2 cells 
were lacking FOXP3 under all circumstances, which was not caused by endogenous 
production of IL-4, since IL-4 neutralization did not restore FOXP3 expression. 
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Predominantly naïve T cells could efficiently upregulate FOXP3, suggesting, that 
effector Th2 cells lack an intrinsic factor or actively repress FOXP3 expression.  
 
 
 
Figure 26: Model of Treg  response to the antigen. 1) Differentiated Tregs and effector T 
cells (Teff) are recruited by chemotaxis to the site of antigen. 2) Generation of Tregs 
following stimulation by the antigen. A) Upon contact to antigen, antigen-specific T effector 
cells proliferate and some of them differentiate into Tregs. B)  Committed effector T cells lost 
their capacity to convert to Tregs and Tregs differentiation has to occur out of naïve T cells.  
 
3.5. Differentiating Th2 cells lack FOXP3 
The commitment to effector cells is characterized by competitive and exclusive 
expression of the corresponding transcription factors, GATA3 or T-Bet, while the 
opposite factor is progressively silenced 100,314. By using in vitro differentiation 
system, in which naïve T cells are treated with IL-12, IL-4 or TGF-β to become Th1, 
Th2 or iTreg, respectively, we observed a similar process during the differentiation 
into FOXP3+ iTregs, which were lacking GATA3 or T-bet expression. In this 
competitive process, TGF-β appeared to be mandatory for the induction of FOXP3, 
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possibly by keeping the expression of GATA3 and T-bet low 315,316,356. In contrast, 
differentiating naïve T cells under neutral, “Th0” conditions showed only a transient 
FOXP3 expression and failed to generate a stable population of FOXP3 expressing 
cells, but GATA3 and T-bet were upregulated. Interestingly, as we and other 
previously described, FOXP3-inducing factors, such as dexamethasone 172, CTLA-4 
222 and estrogens 223, are also known as inhibitor of GATA3 expression 224-227. TGF-β 
is a molecule with pleiotropic effects on cell proliferation, differentiation, migration, 
and survival that affect multiple biological processes 357. 
TGF-β mediates its biological functions via binding to type I and II transmembrane 
kinase receptors and phosphorylates intracellular SMAD proteins whose nuclear 
localization is required for the transcriptional regulation of target genes 358-360. After 
association with SMAD4, SMAD2 translocate into the nucleus to bind to SBE (Smad-
binding element). SMAD complexes control gene expression by recruiting 
coactivators that contain histone-acetyl transferase (HAT) activity or histone-
deacetylase (HDAC) activity–containing corepressors to activate or repress target 
genes, respectively 361. Studies using cells that are deficient in SMAD4 and in the 
expression of dominant-negative SMADs support the existence of Smad-independent 
TGF-β signaling pathways 362,363. 
Therefore TGF-β might modulate the expression of FOXP3 by different mechanisms. 
No direct effect of TGF-β was seen on the FOXP3 promoter in transfected CD4+ T 
cells, indicating that TGF-β might act indirectly by influencing expression of other 
factors, by binding to other regulatory elements of the FOXP3 genes, or modulate 
chromatin structure. Interestingly IL-4 was antagonizing TGF-β effect during 
differentiation of naïve T cells into Tregs. IL-4 has already been shown to negatively 
regulate the development into Th1 or Th17 cells 65,67.  
 
3.6. GATA3 inhibits FOXP3 expression 
GATA3 has been demonstrated to inhibit Th1 commitment during Th2 
differentiation. We demonstrated that overexpression of GATA3 inhibited the FOXP3 
mRNA expression in naïve CD4 T cells. 
Strikingly the DO11.10 CD2GATA3 mice, which overexpress GATA3 under the 
control of the CD2 Locus Control Region (LCR) have less FOXP3+ cells. In addition, 
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the FOXP3- T cells cannot be induced to express FOXP3. Interestingly, these mice do 
not develop autoimmunity. This can be explained by homeostatic expansion or other 
mechanisms are involved in repressing GATA3 activity like ROG 326,364,365 or FOG-1 
366,367 and -2. ROG has been shown to negatively regulate GATA3 activity in CD8 
cells. Even when CD8 cells where overexpressing GATA3 they were unable to 
produce as much IL-4 as CD4 cells do 326. In addition, ROG has been shown to 
mediate this effect by sequestering GATA3. In thymocytes GATA3 induces 
differentiation into CD4. However, when ROG was overexpressed in thymocytes they 
differentiated into the CD8 lineage 325. Preliminary data indicate that ROG is 
expressed by Tregs 142. 
Overexpression of GATA3 has already been described to promote airway 
hyperresponsiveness 302, whereas overexpression of a dominant negative form of this 
transcription factor 304 or treatment with antisense-induced GATA3 blockade 305 in 
mice decreased the severity of the disease. In addition, it has been shown in an OVA-
tolerance model that co-treatment of mice with cholera toxin, which induces GATA3 
expression was able to break tolerance induction 303. It was thought that GATA3 
induces effector functions by stimulating IL-4 and IL-13 secretion. We now describe 
a new role of GATA3 in promoting the immune response by repressing the generation 
of FOXP3+ regulatory cells, representing an important checkpoint to avoid cells 
developping suppressive or anergic phenotype and keep an immune response working 
until clearance of the pathogen. Under inflammatory conditions the naïve cells “see” 
the antigen in a pro-inflammatory environment and elimination of antigens is 
mandatory to avoid damage to the host. Induction of GATA3 might be a mechanism 
to limit the generation of unwanted Tregs. 
GATA3 is probably not the only factor negatively regulating FOXP3 expression, 
since the GATA3-deficient naïve T cells develop spontaneously into Th1 cells or 
IFN-γ-secreting cells, under Th2 differentiation conditions 327, rather than becoming 
Treg. However they only produced a low amount of IFN-γ, which was not 
comparable with Th1 cells, but this suggests that Treg commitment is not a default 
pathway. T-bet, the master factor in Th1 cell differentiation might be a candidate, 
since mutation of a T-bet consensus binding site in the human FOXP3 promoter 
resulted in an increase of the promoter activity in CD4+ T cells (unpublished data). 
However, T-bet functions rather as an activator of transcription 314. 
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3.7. GATA3 represses the FOXP3 promoter activity 
We further demonstrated that GATA3 represses FOXP3 expression by direct binding 
to the promoter. A mutation in the human FOXP3 promoter, disrupting GATA3 
binding site was increasing the luciferase activity in transfected CD4+ T cells. The 
repressor function of GATA3 on FOXP3 promoter activity was further demonstrated 
by cotransfection of GATA3 with the FOXP3 luciferase construct. GATA3 has been 
mainly described as a transcription factor, which, induces transcription by chromatin 
remodelling 110 or directly transactivating promoters 100. However, its function as a 
repressor is still unclear, but it has already been described as a repressor of STAT4 102 
and other genes 328,329,368. The TCR transactivates the FOXP3 promoter in an AP-1-
NFATc2-mediated fashion 310 and GATA3 might compete with the binding of NFAT 
to the promoter at the time of activation (unpublished observations) acting as a 
repressor by being a weaker inducer than NFATc2-AP-1. In addition, GATA3 might 
act by recruiting co-repressor complex to the promoter. 
 
3.8. Effect of IL-4 on committed Tregs 
Although the IL-4R is expressed and functional on Tregs 322, both induced and 
naturally occurring Tregs did not convert to effector or FOXP3- T cells upon 
treatment with IL-4, indicating that after the commitment, the cells have imprinted 
their phenotype. One explanation might be the expression of an inhibitor of the IL-4 
signalling. It has been shown that once committed, the cell looses their capacity to 
convert easily to another phenotype, although some flexibility exists 109. Interestingly, 
we found that the Treg cells were not able to induce GATA3 mRNA as much as the 
CD25- cells did.  Therefore it can be hypothetized that FOXP3 acts as a repressor of 
GATA3, since loss of FOXP3 expression seems to restore an effector phenotype as 
shown in the following examples: IPEX patients bearing a mutated FOXP3 and 
unfunctional FOXP3 have autoreactive FOXP3+ T cells 306, indicating that whitout a 
functional FOXP3, the Tregs acquired an effector phenotype. In addition, it has been 
described using cells of Phemphigus Vulgaris (PV) patients, a severe autoimmune 
bullous skin disorder that Tr1 cells expressing FOXP3 transfected with siRNA against 
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FOXP3 developed into a Th2 phenotype 369. Further suggesting that FOXP3 may 
negatively regulate GATA3 expression. 
 
3.9. Effect of IL-4 on Tregs in vivo 
In order to analyze the in vivo effect of IL-4 on Tregs, we injected a complex of IL-4 
and IL-4 antibody to B6 mice every other day during seven days. The number and 
frequency of CD4+CD25+ (as well as CD4+FOXP3+) diminished by half. In these 
experimental settings, we cannot distinguish whether this drop is caused by a loss of 
thymic naturally-occuring Tregs or peripherally generated Tregs. According to their 
turnover in vivo, Tregs are composed of two subsets: one quiescent with long-life 
span (over 70 days) and the other fraction has a rapid turnover, which is characterized 
by autoreactive Tregs being continuously activated by tissue self-antigens 370. 
Furthermore Tregs have short telomeres indicating that they are highly differentiated 
cells, which have experienced antigenic stimulation 171 and are long-lived cells. Thus, 
probably that IL-4 also acts on generation, cells death and conversion of Tregs. 
IL-4 and IL-13 have been shown to convert human CD4+CD25- naïve T cells into 
CD4+CD25+ Tregs in vitro. We showed that administration of neutralizing antibodies 
against IL-4 or IL-13 broke oral tolerance in an antigen-specific manner in a mouse 
model, with a reduced number of Tregs, suggesting a role for IL-4 and IL-13 in the 
generation of antigen-specific Tregs during oral tolerance. However in this study 
FOXP3 was not measured. Since IL-4 has been described as a growth factor for Tregs 
322, it should have been distinguished between true generation and proliferation of 
CD4+CD25-FOXP3+ induced by IL-4 331. In addition the increase of CD4+CD25+ in 
presence of IL-4 was low. As it was described for IL-2 and IL-4 some cytokine 
neutralizing antibodies in vitro have indeed the opposite effect in vivo, when injected 
into mice. The mechanism is unknown but the antibodies might build complexes with 
the cytokines and thus potentiates its effect 313 making difficult to interpret this result.  
The observation that GATA3 represses and avoid activation of the FOXP3 promoter, 
suggests that at the time of priming the strength of the TCR signaling and the 
cytokines present in the environment are decisive not only in converting naïve T cells 
to Th1 or Th2, but also in inducing regulatory T cells. A competition of transcription 
factors may decide, which direction the immune response will take in order to 
efficiently fight the antigen. This results from the signals given by the innate immune 
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system and cells, which were previously in contact with the pathogens. Therefore 
allowing specificity and flexibility to the adaptive system to fight and clear the 
pathogens.  
 
3.10. Conclusion and outlook 
Taken together, we have identified and characterized the human FOXP3 promoter in 
primary CD4+ T cells. We could explain the molecular mechanisms involved in 
FOXP3 upregulation following TCR triggering and described that GATA3 acts as an 
inhibitor of FOXP3 expression that binds directly and represses the FOXP3 promoter 
(Figure 27). Given the high diversity of T cell subtypes and responses it seems that a 
hierarchy of mechanisms has evolved during CD4 effector cells development at the 
transcriptional level to place stringent controls on Th-cell development.  
Understanding the molecular mechanisms of Treg induction in the periphery gives 
new perspectives in generating antigen-specific Treg cells, which can efficiently 
control autoimmune diseases and allergies. On the other hand inhibiting regulatory T 
cells 185 in the tumor environment will boost the tumor-immunity. The results of this 
thesis not only gives new insights into the molecular mechanisms involved into 
FOXP3 expression and Treg generation, but may also be the starting point for the 
design of new therapeutical approaches targeting IL-4 in order to modulate Treg 
development. 
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Figure 27: FOXP3 gene regulation in primary T cells. TCR triggering by activating NFAT 
and AP-1 is a positive regulator of FOXP3 promoter activity, whereas IL-4 by inducing 
GATA3 expression acts as negative signal. 
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